National Health (Continued Dispensing – Emergency Measures) Determination 2020 (Cth)
Case
No judgment structure available for this case.
National Health (Continued Dispensing – Emergency Measures) Determination 2020
made under subsection 89A(3) of the
National Health Act 1953
Compilation No. 26
Compilation date: 1 April 2022
Includes amendments up to: F2022L00447
Registered: 4 May 2022
About this compilation
This compilation
This is a compilation of the National Health (Continued Dispensing – Emergency Measures) Determination 2020 that shows the text of the law as amended and in force on 1 April 2022 (the compilation date).
The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.
Uncommenced amendments
The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register ( The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.
Application, saving and transitional provisions for provisions and amendments
If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.
Editorial changes
For more information about any editorial changes made in this compilation, see the endnotes.
Modifications
If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.
Self‑repealing provisions
If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.
Contents
Part 1—Preliminary 1
1.01....... Name............................................................................................................................. 1
1.03....... Authority....................................................................................................................... 1
1.04....... Definitions..................................................................................................................... 1
1.05....... Purpose......................................................................................................................... 1
1.06....... Operation of this instrument.......................................................................................... 1
Part 2—Conditions 3
2.01....... General.......................................................................................................................... 3
2.02....... Not practicable to obtain prescription............................................................................ 3
2.03....... Previous supply of pharmaceutical benefit.................................................................... 3
2.04....... Stability of therapy........................................................................................................ 3
2.05....... Prior clinical review by PBS prescriber......................................................................... 3
2.06....... Prescription for last supply of pharmaceutical benefit................................................... 4
2.07....... Continued dispensing in previous 12 months................................................................ 4
2.08....... Declaration by person supplied with pharmaceutical benefit......................................... 4
2.09....... Maximum quantity of supply........................................................................................ 4
2.10....... Preparing and recording information............................................................................. 4
Part 3—Pharmaceutical benefits 6
3.01....... Pharmaceutical benefits................................................................................................. 6
Schedule 1 – Pharmaceutical Benefits 7
Endnotes115
Endnote 1—About the endnotes 115
Endnote 2—Abbreviation key 116
Endnote 3—Legislation history 117
Endnote 4—Amendment history 121
Part 1—Preliminary
1.01 Name
This instrument is the National Health (Continued Dispensing – Emergency Measures) Determination 2020.
1.03 Authority
This instrument is made under subsection 89A(3) of the National Health Act 1953.
1.04 Definitions
(1) In this determination:
Act means the National Health Act 1953.
prescriber bag provisions has the meaning given by subsection 84(1) of the Act.
PSA Guidelines means the document titled Guidelines for the Continued Dispensing of eligible prescribed medicines by pharmacists, issued by the Pharmaceutical Society of Australia.
requested supply: see subsection 2.01(1).
(2) In this determination, the following terms have the same meaning as in Part VII of the Act:
· approved pharmacist
· listed brand
· PBS prescriber
· pharmaceutical benefit
· pharmaceutical item.
· Schedule equivalent
1.05 Purpose
This determination specifies the pharmaceutical benefits that may be supplied, and the conditions that must be satisfied when those pharmaceutical benefits are supplied, by an approved pharmacist without a current prescription, but on the basis of a previous prescription from a PBS prescriber.
1.06 Operation of this instrument
This instrument does not apply to the following:
(a) the supply of pharmaceutical benefits in accordance with special arrangements under section 100 of Act; and
(b) the supply of pharmaceutical benefits under the prescriber bag provisions under Part VII of the Act.
Part 2—Conditions
2.01 General
(1) For paragraph 89A(3)(b) of the Act, this Part sets out the conditions that must be satisfied when making a supply (the requested supply) of a pharmaceutical benefit to a person under subsection 89A(1) of the Act.
(2) An approved pharmacist must consider the PSA Guidelines when:
(a) satisfying the conditions set out in this Part; or
(b) deciding whether those conditions are satisfied.
(3) In this Part:
(a) a reference to the person is a reference to the person who requested the supply of a pharmaceutical benefit under subsection 89A(1) of the Act; and
(b) a reference to the PBS prescriber is a reference to the PBS prescriber who most recently prescribed the supply of the pharmaceutical benefit to the person.
(c) a reference to “the pharmaceutical benefit” in sections 2.03, 2.05, 2.06 and 2.07 includes a pharmaceutical benefit that is Schedule equivalent.
2.02 Not practicable to obtain prescription
A condition is that the approved pharmacist is satisfied that it is not practicable for the person to obtain a prescription for the pharmaceutical benefit from a PBS prescriber before the person needs the supply of the pharmaceutical benefit.
2.03 Previous supply of pharmaceutical benefit
A condition is that the approved pharmacist is satisfied that:
(a) the person has previously been supplied the pharmaceutical benefit on the basis of a prescription from a PBS prescriber; and
(b) the PBS prescriber prescribed the supply of the pharmaceutical benefit for the person in at least one of the circumstances determined for that pharmaceutical benefit under paragraph 85(7)(b) of the Act.
Note: The circumstances determined under paragraph 85(7)(b) of the Act relate to pharmaceutical benefits that are relevant pharmaceutical benefits under section 88A of the Act.
2.04 Stability of therapy
A condition is that the approved pharmacist is satisfied that the person’s therapy is stable.
2.05 Prior clinical review by PBS prescriber
A condition is that the approved pharmacist is satisfied that:
(a) the person has been taking the pharmaceutical benefit regularly for an uninterrupted period; and
(b) since the start of that period, the PBS prescriber has assessed the person’s condition and decided that there is a need for ongoing treatment with the pharmaceutical benefit.
Note: See paragraph 2.01(3)(b) for references to the PBS prescriber.
2.06 Prescription for last supply of pharmaceutical benefit
A condition is that the approved pharmacist is satisfied that the person had a valid prescription under Part VII of the Act for the last supply of the pharmaceutical benefit to the person before the requested supply.
2.07 Continued dispensing in previous 12 months
A condition is that the approved pharmacist is satisfied that the person was not supplied with the pharmaceutical benefit under subsection 89A(1) of the Act in the 12 months before the requested supply.
2.08 Declaration by person supplied with pharmaceutical benefit
A condition is that the person, or an agent of the person (other than the approved pharmacist), signs a declaration acknowledging that the person is being supplied with the pharmaceutical benefit without the presentation of a valid prescription under Part VII of the Act.
2.09 Maximum quantity of supply
A condition is that the approved pharmacist supplies the quantity or number of units of the pharmaceutical item in the pharmaceutical benefit determined under paragraph 85A(2)(a) of the Act that is the same quantity or number of units of the pharmaceutical item that was previously supplied under the prescription referred to in section 2.06.
2.10 Preparing and recording information
(1) A condition is that, when the pharmaceutical benefit is supplied, the approved pharmacist:
(a) records the information that the pharmacist used to support his or her decision to supply the pharmaceutical benefit; and
(b) prepares information about the supply that the pharmacist will send to the PBS prescriber.
Note: See the PSA Guidelines for guidance about when the information should be sent to the PBS prescriber.
(2) The information that must be recorded and prepared includes the following:
(a) a statement that the pharmaceutical benefit supplied is a pharmaceutical benefit determined under paragraph 89A(3)(a) of the Act;
(b) a statement that the conditions mentioned in sections 2.02 to 2.05 are satisfied;
(c) a statement that the approved pharmacist is satisfied that the pharmaceutical benefit needs to be supplied to the person to facilitate continuity of treatment.
Part 3—Pharmaceutical benefits
3.01 Pharmaceutical benefits
(1) For subsection 89A(3)(a) of the Act, an approved pharmacist may supply without a prescription a pharmaceutical benefit, being any listed brand of a pharmaceutical item mentioned in Schedule 1.
(2) For subsection (1), the pharmaceutical item is the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
Schedule 1 – Pharmaceutical Benefits
(section 3.01)
| Listed Drug | Form | Manner of Administration |
| Abatacept | Injection 125 mg in 1 mL single dose autoinjector | Injection |
| Injection 125 mg in 1 mL single dose pre‑filled syringe | Injection | |
| Abemaciclib | Tablet 100 mg | Oral |
| Tablet 150 mg | Oral | |
| Tablet 50 mg | Oral | |
| Abiraterone | Tablet containing abiraterone acetate 250 mg | Oral |
| Tablet containing abiraterone acetate 500 mg | Oral | |
| Acalabrutinib | Capsule 100 mg | Oral |
| Acamprosate | Tablet (enteric coated) containing acamprosate calcium 333 mg | Oral |
| Acarbose | Tablet 100 mg | Oral |
| Tablet 50 mg | Oral | |
| Acetazolamide | Tablet 250 mg | Oral |
| Aciclovir | Eye ointment 30 mg per g, 4.5 g | Application to the eye |
| Tablet 200 mg | Oral | |
| Tablet 800 mg | Oral | |
| Acitretin | Capsule 10 mg | Oral |
| Capsule 25 mg | Oral | |
| Aclidinium | Powder for oral inhalation in breath actuated device 322 micrograms (as bromide) per dose, 60 doses | Inhalation by mouth |
| Aclidinium with formoterol | Powder for oral inhalation in breath actuated device containing aclidinium 340 micrograms (as bromide) with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth |
| Adalimumab | Injection 20 mg in 0.2 mL pre‑filled syringe | Injection |
| Injection 20 mg in 0.4 mL pre‑filled syringe | Injection | |
| Injection 40 mg in 0.4 mL pre‑filled pen | Injection | |
| Injection 40 mg in 0.4 mL pre‑filled syringe | Injection | |
| Injection 40 mg in 0.8 mL pre‑filled pen | Injection | |
| Injection 40 mg in 0.8 mL pre‑filled syringe | Injection | |
| Injection 80 mg in 0.8 mL pre‑filled pen | Injection | |
| Injection 80 mg in 0.8 mL pre‑filled syringe | Injection | |
| Adapalene with benzoyl peroxide | Gel 1 mg‑25 mg per g, 30 g | Application |
| Adrenaline (epinephrine) | I.M. injection 150 micrograms in 0.3 mL single dose syringe auto‑injector | Injection |
| I.M. injection 300 micrograms in 0.3 mL single dose syringe auto‑injector | Injection | |
| I.M. injection 500 micrograms in 0.3 mL single dose syringe auto‑injector | Injection | |
| Injection 1 mg (as acid tartrate) in 1 mL (1 in 1,000) | Injection | |
| Afatinib | Tablet 20 mg | Oral |
| Tablet 30 mg | Oral | |
| Tablet 40 mg | Oral | |
| Tablet 50 mg | Oral | |
| Aflibercept | Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre‑filled syringe | Injection |
| Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL) | Injection | |
| Albendazole | Tablet 200 mg | Oral |
| Tablet 400 mg | Oral | |
| Alectinib | Capsule 150 mg | Oral |
| Alendronic acid | Tablet 70 mg (as alendronate sodium) | Oral |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol | Oral |
| Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol | Oral | |
| Alirocumab | Injection 75 mg in 1 mL single use pre‑filled pen | Injection |
| Injection 150 mg in 1 mL single use pre‑filled pen | Injection | |
| Allopurinol | Tablet 100 mg | Oral |
| Tablet 300 mg | Oral | |
| Alogliptin | Tablet 12.5 mg (as benzoate) | Oral |
| Tablet 25 mg (as benzoate) | Oral | |
| Tablet 6.25 mg (as benzoate) | Oral | |
| Alogliptin with metformin | Tablet containing 12.5 mg alogliptin (as benzoate) with 1 g metformin hydrochloride | Oral |
| Tablet containing 12.5 mg alogliptin (as benzoate) with 500 mg metformin hydrochloride | Oral | |
| Tablet containing 12.5 mg alogliptin (as benzoate) with 850 mg metformin hydrochloride | Oral | |
| Alprazolam | Tablet 1 mg | Oral |
| Tablet 250 micrograms | Oral | |
| Tablet 500 micrograms | Oral | |
| Amantadine | Capsule containing amantadine hydrochloride 100 mg | Oral |
| Amino acid formula supplemented with prebiotics, probiotics and long chain polyunsaturated fatty acids | Oral powder 400 g (Neocate Syneo) | Oral |
| Amino acid formula with carbohydrate, vitamins, minerals and trace elements without phenylalanine | Sachets containing oral powder 20 g, 30 (PKU Go) | Oral |
| Amino acid formula with carbohydrate without phenylalanine | Tablets containing 0.92 g protein, 462 (PKU Easy Tablet) | Oral |
| Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine | Bottles containing oral powder 34 g, 30 (PKU Easy Shake & Go) | Oral |
| Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine and tyrosine | Bottles containing oral powder 34 g, 30 (TYR Easy Shake & Go) | Oral |
| Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine and tyrosine, and supplemented with docosahexanoic acid | Oral liquid 125 mL, 36 (TYR Anamix junior LQ) | Oral |
| Amino acid formula with fat, carbohydrate, vitamins, minerals, and trace elements, without methionine and supplemented with docosahexanoic acid | Oral liquid 125 mL, 36 (HCU Anamix junior LQ) | Oral |
| Amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides | Oral powder 400 g (Alfamino Junior) | Oral |
| Oral powder 400 g (Neocate Junior) | Oral | |
| Oral powder 800 g (Essential Care Jr) | Oral | |
| Amino acid formula with fat, carbohydrate without methionine | Tablets containing 0.91 g protein, 462 (HCU Easy Tablet) | Oral |
| Amino acid formula with fat, carbohydrate without phenylalanine | Tablets (modified release), 70.8 g protein per 100 g, 110 g, 4 (PKU Easy Microtabs) | Oral |
| Amino acid formula with fat, carbohydrate without phenylalanine and tyrosine | Tablets containing 0.91 g protein, 462 (TYR Easy Tablet) | Oral |
| Amino acid formula with fat, carbohydrate without valine, leucine and isoleucine | Tablets containing 0.91 g protein, 462 (MSUD Easy Tablet) | Oral |
| Amino acid formula with vitamins and minerals without lysine and low in tryptophan | Oral powder 400 g (GA1 Anamix infant) | Oral |
| Oral powder 500 g (XLYS, LOW TRY Maxamum) | Oral | |
| Sachets containing oral powder 18 g, 30 (GA1 Anamix Junior) | Oral | |
| Sachets containing oral powder 24 g, 30 (GA gel) | Oral | |
| Sachets containing oral powder 25 g, 30 (GA express 15) | Oral | |
| Amino acid formula with vitamins and minerals without methionine | Oral liquid 125 mL, 30 (HCU Lophlex LQ 20) | Oral |
| Oral liquid 130 mL, 30 (HCU cooler 15) | Oral | |
| Oral liquid 174 mL, 30 (HCU cooler 20) | Oral | |
| Oral liquid 87 mL, 30 (HCU cooler 10) | Oral | |
| Oral powder 400 g (HCU Anamix infant) | Oral | |
| Oral powder 500 g (XMET Maxamum) | Oral | |
| Sachets containing oral powder 24 g, 30 (HCU gel) | Oral | |
| Sachets containing oral powder 25 g, 30 (HCU express 15) | Oral | |
| Sachets containing oral powder 29 g, 30 (HCU Lophlex) | Oral | |
| Sachets containing oral powder 36 g, 30 (HCU Anamix Junior) | Oral | |
| Amino acid formula with vitamins and minerals without methionine, threonine and valine and low in isoleucine | Oral powder 400 g (MMA/PA Anamix infant) | Oral |
| Oral powder 500 g (XMTVI Maxamum) | Oral | |
| Sachets containing oral powder 18 g, 30 (MMA/PA Anamix Junior) | Oral | |
| Sachets containing oral powder 24 g, 30 (MMA/PA gel) | Oral | |
| Sachets containing oral powder 25 g, 30 (MMA/PA express 15) | Oral | |
| Amino acid formula with vitamins and minerals without phenylalanine | Oral gel 85 g, 30 (PKU squeezie) | Oral |
| Oral liquid 125 mL, 30 (PKU Lophlex LQ 20) | Oral | |
| Oral liquid 125 mL, 36 (PKU Anamix Junior LQ) | Oral | |
| Oral liquid 130 mL, 30 (PKU Air 15) | Oral | |
| Oral liquid 130 mL, 30 (PKU Cooler 15) | Oral | |
| Oral liquid 174 mL, 30 (PKU Air 20) | Oral | |
| Oral liquid 174 mL, 30 (PKU Cooler 20) | Oral | |
| Oral liquid 250 mL (Easiphen) | Oral | |
| Oral liquid 62.5 mL, 60 (PKU Lophlex LQ 10) | Oral | |
| Oral liquid 87 mL, 30 (PKU Cooler 10) | Oral | |
| Oral powder 500 g (XP Maxamum) | Oral | |
| Oral semi‑solid 109 g, 36 (PKU Lophlex Sensation 20) | Oral | |
| Sachets containing oral powder 24 g, 30 (PKU gel) | Oral | |
| Sachets containing oral powder 25 g, 30 (PKU express 15) | Oral | |
| Sachets containing oral powder 28 g, 30 (PKU Lophlex) | Oral | |
| Sachets containing oral powder 34 g, 30 (PKU express 20) | Oral | |
| Sachets containing oral powder 36 g, 30 (PKU Anamix Junior) | Oral | |
| Amino acid formula with vitamins and minerals without phenylalanine and tyrosine | Oral liquid 125 mL, 30 (TYR Lophlex LQ 20) | Oral |
| Oral liquid 130 mL, 30 (TYR cooler 15) | Oral | |
| Oral liquid 174 mL, 30 (TYR cooler 20) | Oral | |
| Oral liquid 87 mL, 30 (TYR cooler 10) | Oral | |
| Oral powder 400 g (TYR Anamix infant) | Oral | |
| Oral powder 500 g (XPhen, Tyr Maxamum) | Oral | |
| Sachets containing oral powder 24 g, 30 (TYR gel) | Oral | |
| Sachets containing oral powder 25 g, 30 (TYR express 15) | Oral | |
| Sachets containing oral powder 28 g, 30 (TYR Lophlex) | Oral | |
| Sachets containing oral powder 36 g, 30 (TYR Anamix Junior) | Oral | |
| Amino acid formula with vitamins and minerals without valine, leucine and isoleucine | Oral liquid 125 mL, 30 (MSUD Lophlex LQ 20) | Oral |
| Oral liquid 130 mL, 30 (MSUD cooler 15) | Oral | |
| Oral liquid 174 mL, 30 (MSUD cooler 20) | Oral | |
| Oral liquid 87 mL, 30 (MSUD cooler 10) | Oral | |
| Oral powder 400 g (MSUD Anamix infant) | Oral | |
| Oral powder 500 g (MSUD AID III) | Oral | |
| Oral powder 500 g (MSUD Maxamum) | Oral | |
| Sachets containing oral powder 24 g, 30 (MSUD gel) | Oral | |
| Sachets containing oral powder 25 g, 30 (MSUD express 15) | Oral | |
| Sachets containing oral powder 28 g, 30 (MSUD Lophlex) | Oral | |
| Sachets containing oral powder 36 g, 30 (MSUD Anamix Junior) | Oral | |
| Amino acid formula with vitamins and minerals without valine, leucine and isoleucine with fat, carbohydrate and trace elements and supplemented with docosahexanoic acid | Oral liquid 125 mL, 36 (MSUD Anamix Junior LQ) | Oral |
| Amino acid formula with vitamins and minerals, low phenylalanine and supplemented with docosahexaenoic acid and arachidonic acid | Sachets containing oral powder 12.5 g, 30 (PKU Anamix First Spoon) | Oral |
| Sachets containing oral powder 12.5 g, 30 (PKU Explore 5) | Oral | |
| Sachets containing oral powder 25 g, 30 (PKU Explore 10) | Oral | |
| Amino acid formula with vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine | Oral powder 400 g (PKU Anamix infant) | Oral |
| Oral powder 400 g (PKU Start) | Oral | |
| Amino acid formula without phenylalanine | Tablets 1 g, 75 (Phlexy‑10) | Oral |
| Amino acid formula without valine, leucine and isoleucine | Sachets containing oral powder 6 g, 30 (MSUD amino5) | Oral |
| Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids | Oral powder 400 g (EleCare LCP) | Oral |
| Oral powder 400 g (Neocate LCP) | Oral | |
| Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides | Oral powder 400 g (Alfamino) | Oral |
| Oral powder 400 g (Neocate Gold) | Oral | |
| Amino acids‑synthetic, formula | Oral powder 400 g (EleCare) | Oral |
| Oral powder 400 g (Neocate Junior Vanilla) | Oral | |
| Amiodarone | Tablet containing amiodarone hydrochloride 100 mg | Oral |
| Tablet containing amiodarone hydrochloride 200 mg | Oral | |
| Amisulpride | Oral solution 100 mg per mL, 60 mL | Oral |
| Tablet 100 mg | Oral | |
| Tablet 200 mg | Oral | |
| Tablet 400 mg | Oral | |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 10 mg | Oral |
| Tablet containing amitriptyline hydrochloride 25 mg | Oral | |
| Tablet containing amitriptyline hydrochloride 50 mg | Oral | |
| Amlodipine | Tablet 10 mg (as besilate) | Oral |
| Tablet 5 mg (as besilate) | Oral | |
| Amlodipine with atorvastatin | Tablet 10 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) | Oral |
| Tablet 10 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) | Oral | |
| Tablet 10 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) | Oral | |
| Tablet 10 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) | Oral | |
| Tablet 5 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) | Oral | |
| Tablet 5 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) | Oral | |
| Tablet 5 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) | Oral | |
| Tablet 5 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) | Oral | |
| Amlodipine with valsartan | Tablet 10 mg (as besilate)‑160 mg | Oral |
| Tablet 10 mg (as besilate)‑320 mg | Oral | |
| Tablet 5 mg (as besilate)‑160 mg | Oral | |
| Tablet 5 mg (as besilate)‑320 mg | Oral | |
| Tablet 5 mg (as besilate)‑80 mg | Oral | |
| Amlodipine with valsartan and hydrochlorothiazide | Tablet 10 mg (as besilate)‑160 mg‑12.5 mg | Oral |
| Tablet 10 mg (as besilate)‑160 mg‑25 mg | Oral | |
| Tablet 10 mg (as besilate)‑320 mg‑25 mg | Oral | |
| Tablet 5 mg (as besilate)‑160 mg‑12.5 mg | Oral | |
| Tablet 5 mg (as besilate)‑160 mg‑25 mg | Oral | |
| Amoxicillin | Capsule 250 mg (as trihydrate) | Oral |
| Capsule 500 mg (as trihydrate) | Oral | |
| Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL | Oral | |
| Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL | Oral | |
| Powder for oral suspension 500 mg (as trihydrate) per 5 mL, 100 mL | Oral | |
| Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL | Oral | |
| Tablet 1 g (as trihydrate) | Oral | |
| Amoxicillin with clavulanic acid | Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL | Oral |
| Powder for oral suspension containing 400 mg amoxicillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL | Oral | |
| Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | |
| Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | |
| Amphotericin B | Lozenge 10 mg | Oral |
| Ampicillin | Powder for injection 1 g (as sodium) | Injection |
| Powder for injection 500 mg (as sodium) | Injection | |
| Amylopectin, modified long chain | Sachets containing oral powder 60 g, 30 (Glycosade) | Oral |
| Anastrozole | Tablet 1 mg | Oral |
| Apixaban | Tablet 2.5 mg | Oral |
| Tablet 5 mg | Oral | |
| Apomorphine | Injection containing apomorphine hydrochloride hemihydrate 20 mg in 2 mL | Injection |
| Injection containing apomorphine hydrochloride hemihydrate 50 mg in 5 mL | Injection | |
| Injection containing apomorphine hydrochloride hemihydrate 100 mg in 20 mL | Injection | |
| Solution for subcutaneous injection containing apomorphine hydrochloride 30 mg in 3 mL pre‑filled pen | Injection | |
| Solution for subcutaneous infusion containing apomorphine hydrochloride hemihydrate 50 mg in 10 mL pre‑filled syringe | Injection | |
| Apraclonidine | Eye drops 5 mg (as hydrochloride) per mL, 10 mL | Application to the eye |
| Apremilast | Pack containing 4 tablets 10 mg, 4 tablets 20 mg and 19 tablets 30 mg | Oral |
| Tablet 30 mg | Oral | |
| Aprepitant | Capsule 165 mg | Oral |
| Arachidonic acid and docosahexaenoic acid with carbohydrate | Sachets of oral powder 4 g containing 200 mg arachidonic acid and 100 mg docosahexaenoic acid, 30 (keyomega) | Oral |
| Arginine with carbohydrate | Sachets of oral powder 4 g containing 2 g arginine, 30 (Arginine 2000) | Oral |
| Sachets of oral powder 4 g containing 500 mg arginine, 30 (Arginine 500) | Oral | |
| Sachets of oral powder 7.6 g containing 5 g arginine, 30 (Arginine 5000) | Oral | |
| Aripiprazole | Powder for injection 300 mg (as monohydrate) with diluent | Injection |
| Powder for injection 400 mg (as monohydrate) with diluent | Injection | |
| Tablet 10 mg | Oral | |
| Tablet 15 mg | Oral | |
| Tablet 20 mg | Oral | |
| Tablet 30 mg | Oral | |
| Armodafinil | Tablet 150 mg | Oral |
| Tablet 250 mg | Oral | |
| Tablet 50 mg | Oral | |
| Artemether with lumefantrine | Tablet (dispersible) 20 mg‑120 mg | Oral |
| Tablet 20 mg‑120 mg | Oral | |
| Asenapine | Sublingual wafer 10 mg (as maleate) | Sublingual |
| Sublingual wafer 5 mg (as maleate) | Sublingual | |
| Aspirin | Tablet 100 mg | Oral |
| Atenolol | Oral solution 50 mg in 10 mL, 300 mL | Oral |
| Tablet 50 mg | Oral | |
| Atomoxetine | Capsule 10 mg (as hydrochloride) | Oral |
| Capsule 100 mg (as hydrochloride) | Oral | |
| Capsule 18 mg (as hydrochloride) | Oral | |
| Capsule 25 mg (as hydrochloride) | Oral | |
| Capsule 40 mg (as hydrochloride) | Oral | |
| Capsule 60 mg (as hydrochloride) | Oral | |
| Capsule 80 mg (as hydrochloride) | Oral | |
| Atorvastatin | Tablet 10 mg (as calcium) | Oral |
| Tablet 20 mg (as calcium) | Oral | |
| Tablet 40 mg (as calcium) | Oral | |
| Tablet 80 mg (as calcium) | Oral | |
| Atovaquone | Oral suspension 750 mg per 5 mL, 210 mL | Oral |
| Atovaquone with proguanil | Tablet containing atovaquone 250 mg with proguanil hydrochloride 100 mg | Oral |
| Atropine | Eye drops containing atropine sulfate monohydrate 10 mg per mL, 15 mL | Application to the eye |
| Injection containing atropine sulfate monohydrate 600 micrograms in 1 mL | Injection | |
| Auranofin | Capsule 3 mg | Oral |
| Tablet 3 mg | Oral | |
| Axitinib | Tablet 1 mg | Oral |
| Tablet 5 mg | Oral | |
| Azathioprine | Tablet 25 mg | Oral |
| Tablet 50 mg | Oral | |
| Azithromycin | Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL | Oral |
| Tablet 500 mg (as dihydrate) | Oral | |
| Baclofen | Tablet 10 mg | Oral |
| Tablet 25 mg | Oral | |
| Balsalazide | Capsule containing balsalazide sodium 750 mg | Oral |
| Baricitinib | Tablet 2 mg | Oral |
| Tablet 4 mg | Oral | |
| Beclometasone | Pressurised inhalation containing beclometasone dipropionate 100 micrograms per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth |
| Pressurised inhalation containing beclometasone dipropionate 50 micrograms per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth | |
| Pressurised inhalation in breath actuated device containing beclometasone dipropionate 100 micrograms per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth | |
| Pressurised inhalation in breath actuated device containing beclometasone dipropionate 50 micrograms per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth | |
| Beclometasone with formoterol | Pressurised inhalation containing beclometasone dipropionate 100 micrograms and formoterol fumarate dihydrate 6 micrograms per dose,120 dose | Inhalation by mouth |
| Beclometasone with formoterol and glycopyrronium | Pressurised inhalation containing beclometasone dipropionate 100 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses | Inhalation by mouth |
| Benzathine benzylpenicillin | Injection containing 1,200,000 units benzathine benzylpenicillin tetrahydrate in 2.3 mL single use pre‑filled syringe | Injection |
| Injection containing 600,000 units benzathine benzylpenicillin tetrahydrate in 1.17 mL single use pre‑filled syringe | Injection | |
| Benzatropine | Injection containing benzatropine mesilate 2 mg in 2 mL | Injection |
| Tablet containing benzatropine mesilate 2 mg | Oral | |
| Benzydamine | Mouth and throat rinse containing benzydamine hydrochloride 22.5 mg per 15 mL, 500 mL | Oral application |
| Benzylpenicillin | Powder for injection 3 g (as sodium) | Injection |
| Powder for injection 600 mg (as sodium) | Injection | |
| Betaine | Oral powder 180 g | Oral |
| Betamethasone | Cream 200 micrograms (as valerate) per g, 100 g | Application |
| Cream 500 micrograms (as dipropionate) per g, 15 g | Application | |
| Cream 500 micrograms (as valerate) per g, 15 g | Application | |
| Injection containing betamethasone acetate 3 mg with betamethasone sodium phosphate 3.9 mg in 1 mL | Injection | |
| Ointment 500 micrograms (as dipropionate) per g, 15 g | Application | |
| Betaxolol | Eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL | Application to the eye |
| Bethanechol | Tablet containing bethanechol hydrochloride 10 mg | Oral |
| Bicalutamide | Tablet 50 mg | Oral |
| Bimatoprost | Eye drops 300 micrograms per mL, 3 mL | Application to the eye |
| Eye drops 300 micrograms per mL, single dose units 0.4 mL, 30 | Application to the eye | |
| Bimatoprost with timolol | Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, 3 mL | Application to the eye |
| Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, single dose units 0.4 mL, 30 | Application to the eye | |
| Binimetinib | Tablet 15 mg | Oral |
| Bisacodyl | Enemas 10 mg in 5 mL, 25 | Rectal |
| Suppositories 10 mg, 10 | Rectal | |
| Suppositories 10 mg, 12 | Rectal | |
| Tablet 5 mg | Oral | |
| Bisoprolol | Tablet containing bisoprolol fumarate 10 mg | Oral |
| Tablet containing bisoprolol fumarate 2.5 mg | Oral | |
| Tablet containing bisoprolol fumarate 5 mg | Oral | |
| Bivalirudin | Powder for I.V. injection 250 mg (as trifluoroacetate) | Injection |
| Brexpiprazole | Tablet 1 mg | Oral |
| Tablet 2 mg | Oral | |
| Tablet 3 mg | Oral | |
| Tablet 4 mg | Oral | |
| Brigatinib | Pack containing 7 tablets 90 mg and 21 tablets 180 mg | Oral |
| Tablet 30 mg | Oral | |
| Tablet 90 mg | Oral | |
| Tablet 180 mg | Oral | |
| Brimonidine | Eye drops containing brimonidine tartrate 1.5 mg per mL, 5 mL | Application to the eye |
| Eye drops containing brimonidine tartrate 2 mg per mL, 5 mL | Application to the eye | |
| Brimonidine with timolol | Eye drops containing brimonidine tartrate 2 mg with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye |
| Brinzolamide | Eye drops 10 mg per mL, 5 mL | Application to the eye |
| Brinzolamide with brimonidine | Eye drops 10 mg brinzolamide with 2 mg brimonidine tartrate per mL, 5 mL | Application to the eye |
| Brinzolamide with timolol | Eye drops 10 mg brinzolamide with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye |
| Brivaracetam | Oral solution 10 mg per mL, 300 mL | Oral |
| Tablet 100 mg | Oral | |
| Tablet 25 mg | Oral | |
| Tablet 50 mg | Oral | |
| Tablet 75 mg | Oral | |
| Brolucizumab | Solution for intravitreal injection 19.8 mg in 0.165 mL pre‑filled syringe | Injection |
| Bromocriptine | Tablet 2.5 mg (as mesilate) | Oral |
| Budesonide | Capsule (modified release) 3 mg | Oral |
| Nebuliser suspension 1 mg in 2 mL single dose units, 30 | Inhalation | |
| Nebuliser suspension 500 micrograms in 2 mL single dose units, 30 | Inhalation | |
| Powder for oral inhalation in breath actuated device 100 micrograms per dose, 200 doses | Inhalation by mouth | |
| Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses | Inhalation by mouth | |
| Powder for oral inhalation in breath actuated device 400 micrograms per dose, 200 doses | Inhalation by mouth | |
| Rectal foam 2 mg per application, 14 applications, aerosol 16.8 g, 2 | Rectal | |
| Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 100 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth |
| Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | |
| Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses, 2 | Inhalation by mouth | |
| Pressurised inhalation containing budesonide 100 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses | Inhalation by mouth | |
| Pressurised inhalation containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | |
| Pressurised inhalation containing budesonide 50 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses | Inhalation by mouth | |
| Budesonide with glycopyrronium and formoterol | Pressurised inhalation containing budesonide 160 micrograms with glycopyrronium 7.2 micrograms and formoterol fumarate dihydrate 5 micrograms per dose, 120 doses | Inhalation by mouth |
| Buprenorphine | Transdermal patch 10 mg | Transdermal |
| Transdermal patch 15 mg | Transdermal | |
| Transdermal patch 20 mg | Transdermal | |
| Transdermal patch 25 mg | Transdermal | |
| Transdermal patch 30 mg | Transdermal | |
| Transdermal patch 40 mg | Transdermal | |
| Transdermal patch 5 mg | Transdermal | |
| Bupropion | Tablet containing bupropion hydrochloride 150 mg (sustained release) | Oral |
| Busulfan | Tablet 2 mg | Oral |
| Cabergoline | Tablet 1 mg | Oral |
| Tablet 2 mg | Oral | |
| Tablet 500 micrograms | Oral | |
| Cabozantinib | Tablet 20 mg | Oral |
| Tablet 40 mg | Oral | |
| Tablet 60 mg | Oral | |
| Calcipotriol with betamethasone | Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g | Application |
| Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g | Application | |
| Calcitonin salmon | Injection 100 I.U. in 1 mL | Injection |
| Calcitriol | Capsule 0.25 microgram | Oral |
| Calcium | Tablet 600 mg (as carbonate) | Oral |
| Tablet, chewable, 500 mg (as carbonate) | Oral | |
| Candesartan | Tablet containing candesartan cilexetil 16 mg | Oral |
| Tablet containing candesartan cilexetil 32 mg | Oral | |
| Tablet containing candesartan cilexetil 4 mg | Oral | |
| Tablet containing candesartan cilexetil 8 mg | Oral | |
| Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg | Oral |
| Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg | Oral | |
| Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg | Oral | |
| Cannabidiol | Oral liquid 100 mg per mL, 100 mL | Oral |
| Capecitabine | Tablet 150 mg | Oral |
| Tablet 500 mg | Oral | |
| Captopril | Oral solution 5 mg per mL, 95 mL | Oral |
| Carbamazepine | Oral suspension 100 mg per 5 mL, 300 mL | Oral |
| Tablet 100 mg | Oral | |
| Tablet 200 mg | Oral | |
| Tablet 200 mg (controlled release) | Oral | |
| Tablet 400 mg (controlled release) | Oral | |
| Carbimazole | Tablet 5 mg | Oral |
| Carbohydrate, fat, vitamins, minerals and trace elements | Oral powder 400 g (Energivit) | Oral |
| Carbohydrate, fat, vitamins, minerals and trace elements and supplemented with arachidonic acid and docosahexaenoic acid | Sachets containing oral powder 43 g, 30 (basecal 200) | Oral |
| Carbomer | Eye gel 2 mg per g, 10 g | Application to the eye |
| Eye gel 2 mg per g, single dose units 0.6 mL, 30 | Application to the eye | |
| Carbomer 974 | Ocular lubricating gel 3 mg per g, single dose units 0.5 g, 30 | Application to the eye |
| Cariprazine | Capsule 1.5 mg | Oral |
| Capsule 3 mg | Oral | |
| Capsule 4.5 mg | Oral | |
| Capsule 6 mg | Oral | |
| Carmellose | Eye drops containing carmellose sodium 10 mg per mL, 15 mL | Application to the eye |
| Eye drops containing carmellose sodium 10 mg per mL, single dose units 0.4 mL, 30 | Application to the eye | |
| Eye drops containing carmellose sodium 5 mg per mL, 10 mL | Application to the eye | |
| Eye drops containing carmellose sodium 5 mg per mL, 15 mL | Application to the eye | |
| Eye drops containing carmellose sodium 5 mg per mL, single dose units 0.4 mL, 30 | Application to the eye | |
| Carmellose with glycerin | Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL | Application to the eye |
| Carmustine | Implants 7.7 mg, 8 | Implantation |
| Carvedilol | Tablet 12.5 mg | Oral |
| Tablet 25 mg | Oral | |
| Tablet 3.125 mg | Oral | |
| Tablet 6.25 mg | Oral | |
| Cefaclor | Powder for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL | Oral |
| Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL | Oral | |
| Tablet (sustained release) 375 mg (as monohydrate) | Oral | |
| Cefalexin | Capsule 250 mg (as monohydrate) | Oral |
| Capsule 500 mg (as monohydrate) | Oral | |
| Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL | Oral | |
| Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL | Oral | |
| Cefazolin | Powder for injection 1 g (as sodium) | Injection |
| Powder for injection 2 g (as sodium) | Injection | |
| Powder for injection 500 mg (as sodium) | Injection | |
| Cefepime | Powder for injection 1 g (as hydrochloride) | Injection |
| Powder for injection 2 g (as hydrochloride) | Injection | |
| Cefotaxime | Powder for injection 1 g (as sodium) |
| Ceftriaxone | Powder for injection 1 g (as sodium) | Injection |
| Powder for injection 2 g (as sodium) | Injection | |
| Powder for injection 500 mg (as sodium) | Injection | |
| Cefuroxime | Powder for oral suspension 125 mg (as axetil) per 5 mL, 100 mL | Oral |
| Tablet 250 mg (as axetil) | Oral | |
| Celecoxib | Capsule 100 mg | Oral |
| Capsule 200 mg | Oral | |
| Ceritinib | Capsule 150 mg | Oral |
| Certolizumab pegol | Injection 200 mg in 1 mL single use pre‑filled syringe | Injection |
| Solution for injection 200 mg in 1 mL pre‑filled pen | Injection | |
| Chlorambucil | Tablet 2 mg | Oral |
| Chloramphenicol | Eye drops 5 mg per mL, 10 mL | Application to the eye |
| Chlorpromazine | Injection containing chlorpromazine hydrochloride 50 mg in 2 mL | Injection |
| Oral solution containing chlorpromazine hydrochloride 25 mg per 5 mL, 100 mL | Oral | |
| Tablet containing chlorpromazine hydrochloride 10 mg | Oral | |
| Tablet containing chlorpromazine hydrochloride 100 mg | Oral | |
| Tablet containing chlorpromazine hydrochloride 25 mg | Oral | |
| Chlortalidone | Tablet 25 mg | Oral |
| Chorionic gonadotrophin | Injection set containing powder for injection 1,500 units, 3 and solvent 1 mL, 3 | Injection |
| Injection set containing powder for injection 1,500 units, 3 and solvent 1 mL, 3 (s19A) | Injection | |
| Ciclesonide | Pressurised inhalation 160 micrograms per dose, 120 doses (CFC‑free formulation) | Inhalation by mouth |
| Pressurised inhalation 80 micrograms per dose, 120 doses (CFC‑free formulation) | Inhalation by mouth | |
| Ciclosporin | Capsule 10 mg | Oral |
| Capsule 100 mg | Oral | |
| Capsule 25 mg | Oral | |
| Capsule 50 mg | Oral | |
| Eye drops 1 mg per mL, single dose units 0.3 mL, 30 | Application to the eye | |
| Oral liquid 100 mg per mL, 50 mL | Oral | |
| Cinacalcet | Tablet 30 mg (as hydrochloride) | Oral |
| Tablet 60 mg (as hydrochloride) | Oral | |
| Tablet 90 mg (as hydrochloride) | Oral | |
| Ciprofloxacin | Ear drops 3 mg (as hydrochloride) per mL, 5 mL | Application to the ear |
| Eye drops 3 mg (as hydrochloride) per mL, 5 mL | Application to the eye | |
| Tablet 250 mg (as hydrochloride) | Oral | |
| Tablet 500 mg (as hydrochloride) | Oral | |
| Tablet 750 mg (as hydrochloride) | Oral | |
| Citalopram | Tablet 10 mg (as hydrobromide) | Oral |
| Tablet 20 mg (as hydrobromide) | Oral | |
| Tablet 40 mg (as hydrobromide) | Oral | |
| Citrulline | Tablet 1 g, 300 (Citrulline Easy) | Oral |
| Citrulline with carbohydrate | Sachets of oral powder 4 g containing 1 g citrulline, 30 (Citrulline 1000) | Oral |
| Cladribine | Tablet 10 mg | Oral |
| Clarithromycin | Powder for oral liquid 250 mg per 5 mL, 50 mL | Oral |
| Tablet 250 mg | Oral | |
| Clindamycin | Capsule 150 mg (as hydrochloride) | Oral |
| Clobetasol | Shampoo containing clobetasol propionate 500 microgram per mL, 125 mL | Application |
| Clomifene | Tablet containing clomifene citrate 50 mg | Oral |
| Clomipramine | Tablet containing clomipramine hydrochloride 25 mg | Oral |
| Clonazepam | Injection 1 mg in 2 mL (set containing solution 1 mg in 1 mL and 1 mL diluent) | Injection |
| Oral liquid 2.5 mg per mL, 10 mL | Oral | |
| Tablet 2 mg | Oral | |
| Tablet 500 micrograms | Oral | |
| Clonidine | Tablet containing clonidine hydrochloride 100 micrograms | Oral |
| Tablet containing clonidine hydrochloride 150 micrograms | Oral | |
| Clopidogrel | Tablet 75 mg (as besilate) | Oral |
| Tablet 75 mg (as hydrogen sulfate) | Oral | |
| Clopidogrel with aspirin | Tablet 75 mg (as hydrogen sulfate)‑100 mg | Oral |
| Cobimetinib | Tablet 20 mg | Oral |
| Codeine | Tablet containing codeine phosphate hemihydrate 30 mg | Oral |
| Codeine with paracetamol | Tablet containing codeine phosphate hemihydrate 30 mg with paracetamol 500 mg | Oral |
| Colchicine | Tablet 500 micrograms | Oral |
| Colestyramine | Sachets containing 4.7 g oral powder (equivalent to 4 g colestyramine), 50 | Oral |
| Cortisone | Tablet containing cortisone acetate 25 mg | Oral |
| Tablet containing cortisone acetate 5 mg | Oral | |
| Crizotinib | Capsule 200 mg | Oral |
| Capsule 250 mg | Oral | |
| Cromoglycic acid | Pressurised inhalation containing sodium cromoglycate 1 mg per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth |
| Cyclophosphamide | Tablet 50 mg (anhydrous) | Oral |
| Cyproterone | Tablet containing cyproterone acetate 100 mg | Oral |
| Tablet containing cyproterone acetate 50 mg | Oral | |
| Dabigatran etexilate | Capsule 110 mg (as mesilate) | Oral |
| Capsule 150 mg (as mesilate) | Oral | |
| Capsule 75 mg (as mesilate) | Oral | |
| Dabrafenib | Capsule 50 mg (as mesilate) | Oral |
| Capsule 75 mg (as mesilate) | Oral | |
| Dantrolene | Capsule containing dantrolene sodium hemiheptahydrate 25 mg | Oral |
| Capsule containing dantrolene sodium hemiheptahydrate 50 mg | Oral | |
| Dapagliflozin | Tablet 10 mg (as propanediol monohydrate) | Oral |
| Dapagliflozin with metformin | Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride | Oral |
| Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 500 mg metformin hydrochloride | Oral | |
| Tablet (modified release) containing 5 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride | Oral | |
| Dapsone | Tablet 100 mg | Oral |
| Tablet 25 mg | Oral | |
| Daratumumab | Solution for subcutaneous injection containing daratumumab 1800 mg in 15 mL | Injection |
| Darolutamide | Tablet 300 mg | Oral |
| Dasatinib | Tablet 100 mg | Oral |
| Tablet 20 mg | Oral | |
| Tablet 50 mg | Oral | |
| Tablet 70 mg | Oral | |
| Degarelix | Powder for injection 120 mg (as acetate), 2, injection set | Injection |
| Powder for injection 80 mg (as acetate), injection set | Injection | |
| Denosumab | Injection 120 mg in 1.7 mL | Injection |
| Injection 60 mg in 1 mL pre‑filled syringe | Injection | |
| Desmopressin | Nasal spray (pump pack) containing desmopressin acetate 10 micrograms per actuation, 50 actuations, 5 mL | Nasal |
| Nasal spray (pump pack) containing desmopressin acetate 10 micrograms per actuation, 50 actuations, 5 mL, USP (Apotex) | Nasal | |
| Nasal spray (pump pack) containing desmopressin acetate 10 micrograms per actuation, 60 actuations, 6 mL | Nasal | |
| Tablet containing desmopressin acetate 200 micrograms | Oral | |
| Wafer 120 micrograms (as acetate) | Sublingual | |
| Wafer 240 micrograms (as acetate) | Sublingual | |
| Desvenlafaxine | Tablet (extended release) 100 mg (as succinate) | Oral |
| Tablet (extended release) 50 mg (as succinate) | Oral | |
| Tablet (modified release) 100 mg | Oral | |
| Tablet (modified release) 100 mg (as benzoate) | Oral | |
| Tablet (modified release) 50 mg | Oral | |
| Tablet (modified release) 50 mg (as benzoate) | Oral | |
| Dexamethasone | Eye drops 1 mg per mL, 5 mL | Application to the eye |
| Intravitreal injection 700 micrograms | Implantation | |
| Tablet 4 mg | Oral | |
| Tablet 500 micrograms | Oral | |
| Dexamethasone with framycetin and gramicidin | Ear drops containing dexamethasone 500 micrograms (as sodium metasulfobenzoate), framycetin sulfate 5 mg and gramicidin 50 micrograms per mL, 8 mL | Application to the ear |
| Dexamfetamine | Tablet containing dexamfetamine sulfate 5 mg | Oral |
| Diazepam | Oral liquid 10 mg per 10 mL, 100 mL | Oral |
| Tablet 2 mg | Oral | |
| Tablet 5 mg | Oral | |
| Diclofenac | Suppository containing diclofenac sodium 100 mg | Rectal |
| Tablet (enteric coated) containing diclofenac sodium 25 mg | Oral | |
| Tablet (enteric coated) containing diclofenac sodium 50 mg | Oral | |
| Dicloxacillin | Capsule 250 mg (as sodium) | Oral |
| Capsule 500 mg (as sodium) | Oral | |
| Digoxin | Paediatric oral solution 50 micrograms per mL, 60 mL | Oral |
| Tablet 250 micrograms | Oral | |
| Tablet 62.5 micrograms | Oral | |
| Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg | Oral |
| Capsule (controlled delivery) containing diltiazem hydrochloride 240 mg | Oral | |
| Capsule (controlled delivery) containing diltiazem hydrochloride 360 mg | Oral | |
| Tablet containing diltiazem hydrochloride 60 mg | Oral | |
| Dimethyl fumarate | Capsule (modified release) 120 mg | Oral |
| Capsule (modified release) 240 mg | Oral | |
| Diphenoxylate with atropine | Tablet containing diphenoxylate hydrochloride 2.5 mg with atropine sulfate monohydrate 25 micrograms | Oral |
| Diphtheria and tetanus vaccine, adsorbed, diluted for adult use | Injection 0.5 mL in pre‑filled syringe | Injection |
| Dipyridamole with aspirin | Capsule 200 mg (sustained release)‑25 mg | Oral |
| Disopyramide | Capsule 100 mg | Oral |
| Domperidone | Tablet 10 mg | Oral |
| Donepezil | Tablet containing donepezil hydrochloride 10 mg | Oral |
| Tablet containing donepezil hydrochloride 5 mg | Oral | |
| Dorzolamide | Eye drops 20 mg (as hydrochloride) per mL, 5 mL | Application to the eye |
| Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye |
| Dosulepin | Capsule containing dosulepin hydrochloride 25 mg | Oral |
| Tablet containing dosulepin hydrochloride 75 mg | Oral | |
| Doxepin | Capsule 10 mg (as hydrochloride) | Oral |
| Capsule 25 mg (as hydrochloride) | Oral | |
| Tablet 50 mg (as hydrochloride) | Oral | |
| Doxycycline | Capsule 100 mg (as hyclate) (containing enteric coated pellets) | Oral |
| Capsule 50 mg (as hyclate) (containing enteric coated pellets) | Oral | |
| Tablet 100 mg (as hyclate) | Oral | |
| Tablet 100 mg (as monohydrate) | Oral | |
| Tablet 50 mg (as hyclate) | Oral | |
| Tablet 50 mg (as monohydrate) | Oral | |
| Dulaglutide | Injection 1.5 mg in 0.5 mL single dose pre‑filled pen | Injection |
| Duloxetine | Capsule 30 mg (as hydrochloride) | Oral |
| Capsule 60 mg (as hydrochloride) | Oral | |
| Dupilumab | Injection 200 mg in 1.14 mL single dose pre‑filled syringe | Injection |
| Injection 300 mg in 2 mL single dose pre‑filled syringe | Injection | |
| Dutasteride | Capsule 500 micrograms | Oral |
| Dutasteride with tamsulosin | Capsule containing dutasteride 500 micrograms with tamsulosin hydrochloride 400 micrograms | Oral |
| Electrolyte replacement, oral | Oral rehydration salts containing glucose monohydrate 3.56 g, sodium chloride 470 mg, potassium chloride 300 mg and sodium acid citrate 530 mg per sachet, 10 | Oral |
| Eletriptan | Tablet 40 mg (as hydrobromide) | Oral |
| Tablet 80 mg (as hydrobromide) | Oral | |
| Empagliflozin | Tablet 10 mg | Oral |
| Tablet 25 mg | Oral | |
| Empagliflozin with linagliptin | Tablet containing 10 mg empagliflozin with 5 mg linagliptin | Oral |
| Tablet containing 25 mg empagliflozin with 5 mg linagliptin | Oral | |
| Empagliflozin with metformin | Tablet containing 12.5 mg empagliflozin with 1 g metformin hydrochloride | Oral |
| Tablet containing 12.5 mg empagliflozin with 500 mg metformin hydrochloride | Oral | |
| Tablet containing 5 mg empagliflozin with 1 g metformin hydrochloride | Oral | |
| Tablet containing 5 mg empagliflozin with 500 mg metformin hydrochloride | Oral | |
| Enalapril | Tablet containing enalapril maleate 10 mg | Oral |
| Tablet containing enalapril maleate 20 mg | Oral | |
| Tablet containing enalapril maleate 5 mg | Oral | |
| Enalapril with hydrochlorothiazide | Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg | Oral |
| Encorafenib | Capsule 50 mg | Oral |
| Capsule 75 mg | Oral | |
| Enoxaparin | Injection containing enoxaparin sodium 100 mg (10,000 I.U. anti‑Xa) in 1 mL pre‑filled syringe | Injection |
| Injection containing enoxaparin sodium 20 mg (2,000 I.U. anti‑Xa) in 0.2 mL pre‑filled syringe | Injection | |
| Injection containing enoxaparin sodium 40 mg (4,000 I.U. anti‑Xa) in 0.4 mL pre‑filled syringe | Injection | |
| Injection containing enoxaparin sodium 60 mg (6,000 I.U. anti‑Xa) in 0.6 mL pre‑filled syringe | Injection | |
| Injection containing enoxaparin sodium 80 mg (8,000 I.U. anti‑Xa) in 0.8 mL pre‑filled syringe | Injection | |
| Entacapone | Tablet 200 mg | Oral |
| Entrectinib | Capsule 200 mg | Oral |
| Enzalutamide | Capsule 40 mg | Oral |
| Eplerenone | Tablet 25 mg | Oral |
| Tablet 50 mg | Oral | |
| Eprosartan | Tablet 400 mg (as mesilate) | Oral |
| Tablet 600 mg (as mesilate) | Oral | |
| Eprosartan with hydrochlorothiazide | Tablet 600 mg eprosartan (as mesilate) with 12.5 mg hydrochlorothiazide | Oral |
| Eptifibatide | Solution for I.V. infusion 75 mg (as acetate) in 100 mL | Injection |
| Solution for I.V. injection 20 mg (as acetate) in 10 mL | Injection | |
| Erlotinib | Tablet 100 mg (as hydrochloride) | Oral |
| Tablet 150 mg (as hydrochloride) | Oral | |
| Tablet 25 mg (as hydrochloride) | Oral | |
| Ertugliflozin | Tablet 15 mg | Oral |
| Tablet 5 mg | Oral | |
| Ertugliflozin with metformin | Tablet containing 2.5 mg ertugliflozin with 1 g metformin hydrochloride | Oral |
| Tablet containing 2.5 mg ertugliflozin with 500 mg metformin hydrochloride | Oral | |
| Tablet containing 7.5 mg ertugliflozin with 1 g metformin hydrochloride | Oral | |
| Tablet containing 7.5 mg ertugliflozin with 500 mg metformin hydrochloride | Oral | |
| Ertugliflozin with sitagliptin | Tablet containing 15 mg ertugliflozin with 100 mg sitagliptin | Oral |
| Tablet containing 5 mg ertugliflozin with 100 mg sitagliptin | Oral | |
| Erythromycin | Capsule 250 mg (containing enteric coated pellets) | Oral |
| Powder for oral liquid 200 mg (as ethyl succinate) per 5 mL, 100 mL | Oral | |
| Powder for oral liquid 400 mg (as ethyl succinate) per 5 mL, 100 mL | Oral | |
| Escitalopram | Oral solution 20 mg (as oxalate) per mL, 15 mL | Oral |
| Tablet 10 mg (as oxalate) | Oral | |
| Tablet 20 mg (as oxalate) | Oral | |
| Esomeprazole | Capsule (enteric) 20 mg (as magnesium) | Oral |
| Capsule (enteric) 40 mg (as magnesium) | Oral | |
| Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | |
| Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | |
| Esomeprazole and clarithromycin and amoxicillin | Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium trihydrate), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate) | Oral |
| Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate) | Oral | |
| Essential amino acids formula | Oral powder 200 g (Essential Amino Acid Mix) | Oral |
| Essential amino acids formula with minerals and vitamin c | Oral powder 400 g (Dialamine) | Oral |
| Essential amino acids formula with vitamins and minerals | Sachets containing oral powder 12.5 g, 50 (EAA Supplement) | Oral |
| Estradiol | Pessary (modified release) 10 micrograms (as hemihydrate) | Vaginal |
| Tablet 2 mg | Oral | |
| Tablet containing estradiol valerate 1 mg | Oral | |
| Tablet containing estradiol valerate 2 mg | Oral | |
| Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28 | Transdermal | |
| Transdermal patches 1.17 mg, 8 | Transdermal | |
| Transdermal patches 1.5 mg (as hemihydrate), 8 | Transdermal | |
| Transdermal patches 1.56 mg, 8 | Transdermal | |
| Transdermal patches 2 mg, 4 | Transdermal | |
| Transdermal patches 3 mg (as hemihydrate), 8 | Transdermal | |
| Transdermal patches 3.8 mg, 4 | Transdermal | |
| Transdermal patches 390 micrograms, 8 | Transdermal | |
| Transdermal patches 5.7 mg, 4 | Transdermal | |
| Transdermal patches 585 micrograms, 8 | Transdermal | |
| Transdermal patches 7.6 mg, 4 | Transdermal | |
| Transdermal patches 750 micrograms (as hemihydrate), 8 | Transdermal | |
| Transdermal patches 780 micrograms, 8 | Transdermal | |
| Estradiol and estradiol with dydrogesterone | Pack containing 14 tablets estradiol 1 mg and 14 tablets estradiol 1 mg with dydrogesterone 10 mg | Oral |
| Pack containing 14 tablets estradiol 2 mg and 14 tablets estradiol 2 mg with dydrogesterone 10 mg | Oral | |
| Estradiol and estradiol with norethisterone | Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate | Transdermal |
| Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate | Transdermal | |
| Estradiol with dydrogesterone | Tablet 1 mg‑5 mg | Oral |
| Estradiol with norethisterone | Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 | Transdermal |
| Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 | Transdermal | |
| Estriol | Pessaries 500 micrograms, 15 | Vaginal |
| Vaginal cream 1 mg per g, 15 g | Application | |
| Etanercept | Injection 50 mg in 1 mL single use auto‑injector, 4 | Injection |
| Injection 50 mg in 1 mL single use dose‑dispenser cartridges, 4 | Injection | |
| Injection set containing 4 vials powder for injection 25 mg and 4 pre‑filled syringes solvent 1 mL | Injection | |
| Injections 50 mg in 1 mL single use pre‑filled syringes, 4 | Injection | |
| Ethosuximide | Capsule 250 mg | Oral |
| Oral solution 250 mg per 5 mL, 200 mL | Oral | |
| Etonogestrel | Subcutaneous implant 68 mg | Implantation |
| Etoposide | Capsule 100 mg | Oral |
| Capsule 50 mg | Oral | |
| Everolimus | Tablet 0.25 mg | Oral |
| Tablet 0.5 mg | Oral | |
| Tablet 0.75 mg | Oral | |
| Tablet 1 mg | Oral | |
| Tablet 10 mg | Oral | |
| Tablet 2.5 mg | Oral | |
| Tablet 5 mg | Oral | |
| Tablet, dispersible, 2 mg | Oral | |
| Tablet, dispersible, 3 mg | Oral | |
| Tablet, dispersible, 5 mg | Oral | |
| Evolocumab | Injection 140 mg in 1 mL single use pre‑filled pen | Injection |
| Injection 420 mg in 3.5 mL single use pre‑filled cartridge | Injection | |
| Exemestane | Tablet 25 mg | Oral |
| Exenatide | Injection solution 10 micrograms per dose in pre‑filled pen, 60 doses | Injection |
| Injection solution 5 micrograms per dose in pre‑filled pen, 60 doses | Injection | |
| Ezetimibe | Tablet 10 mg | Oral |
| Ezetimibe and rosuvastatin | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) | Oral |
| Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) | Oral | |
| Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) | Oral | |
| Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium) | Oral | |
| Ezetimibe with atorvastatin | Tablet 10 mg‑10 mg | Oral |
| Tablet 10 mg‑20 mg | Oral | |
| Tablet 10 mg‑40 mg | Oral | |
| Tablet 10 mg‑80 mg | Oral | |
| Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | Oral |
| Tablet 10 mg‑20 mg | Oral | |
| Tablet 10 mg‑40 mg | Oral | |
| Tablet 10 mg‑80 mg | Oral | |
| Famciclovir | Tablet 125 mg | Oral |
| Tablet 250 mg | Oral | |
| Tablet 500 mg | Oral | |
| Famotidine | Tablet 20 mg | Oral |
| Tablet 40 mg | Oral | |
| Febuxostat | Tablet 80 mg | Oral |
| Felodipine | Tablet 10 mg (extended release) | Oral |
| Tablet 2.5 mg (extended release) | Oral | |
| Tablet 5 mg (extended release) | Oral | |
| Fenofibrate | Tablet 145 mg | Oral |
| Tablet 48 mg | Oral | |
| Fentanyl | Lozenge 1200 micrograms (as citrate) | Buccal |
| Lozenge 1600 micrograms (as citrate) | Buccal | |
| Lozenge 200 micrograms (as citrate) | Buccal | |
| Lozenge 400 micrograms (as citrate) | Buccal | |
| Lozenge 600 micrograms (as citrate) | Buccal | |
| Lozenge 800 micrograms (as citrate) | Buccal | |
| Tablet (orally disintegrating) 100 micrograms (as citrate) | Buccal | |
| Tablet (orally disintegrating) 200 micrograms (as citrate) | Buccal | |
| Tablet (orally disintegrating) 400 micrograms (as citrate) | Buccal | |
| Tablet (orally disintegrating) 600 micrograms (as citrate) | Buccal | |
| Tablet (orally disintegrating) 800 micrograms (as citrate) | Buccal | |
| Tablet (sublingual) 100 micrograms (as citrate) | Sublingual | |
| Tablet (sublingual) 200 micrograms (as citrate) | Sublingual | |
| Tablet (sublingual) 300 micrograms (as citrate) | Sublingual | |
| Tablet (sublingual) 400 micrograms (as citrate) | Sublingual | |
| Tablet (sublingual) 600 micrograms (as citrate) | Sublingual | |
| Tablet (sublingual) 800 micrograms (as citrate) | Sublingual | |
| Transdermal patch 1.28 mg | Transdermal | |
| Transdermal patch 10.20 mg | Transdermal | |
| Transdermal patch 12.375 mg | Transdermal | |
| Transdermal patch 12.6 mg | Transdermal | |
| Transdermal patch 16.5 mg | Transdermal | |
| Transdermal patch 16.8 mg | Transdermal | |
| Transdermal patch 2.063 mg | Transdermal | |
| Transdermal patch 2.1 mg | Transdermal | |
| Transdermal patch 2.55 mg | Transdermal | |
| Transdermal patch 4.125 mg | Transdermal | |
| Transdermal patch 4.2 mg | Transdermal | |
| Transdermal patch 5.10 mg | Transdermal | |
| Transdermal patch 7.65 mg | Transdermal | |
| Transdermal patch 8.25 mg | Transdermal | |
| Transdermal patch 8.4 mg | Transdermal | |
| Ferric carboxymaltose | Injection 1000 mg (iron) in 20 mL | Injection |
| Injection 500 mg (iron) in 10 mL | Injection | |
| Ferric derisomaltose | Injection 500 mg (iron) in 5 mL | Injection |
| Injection 1000 mg (iron) in 10 mL | Injection | |
| Ferrous fumarate | Tablet 200 mg (equivalent to 65.7 mg iron) | Oral |
| Ferrous fumarate with folic acid | Tablet 310 mg (equivalent to 100 mg iron)‑350 micrograms | Oral |
| Ferrous sulfate | Oral liquid containing 30 mg ferrous sulfate heptahydrate per mL, 250 mL | Oral |
| Fingolimod | Capsule 250 micrograms (as hydrochloride) | Oral |
| Capsule 500 micrograms (as hydrochloride) | Oral | |
| Flecainide | Tablet containing flecainide acetate 100 mg | Oral |
| Tablet containing flecainide acetate 50 mg | Oral | |
| Flucloxacillin | Capsule 250 mg (as sodium monohydrate) | Oral |
| Capsule 500 mg (as sodium monohydrate) | Oral | |
| Powder for injection 1 g (as sodium monohydrate) | Injection | |
| Powder for oral liquid 125 mg (as sodium monohydrate) per 5 mL, 100 mL | Oral | |
| Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL | Oral | |
| Fluconazole | Capsule 100 mg | Oral |
| Capsule 200 mg | Oral | |
| Capsule 50 mg | Oral | |
| Powder for oral suspension 50 mg in 5 mL, 35 mL | Oral | |
| Solution for I.V. infusion 200 mg in 100 mL | Injection | |
| Solution for I.V. infusion 400 mg in 200 mL | Injection | |
| Fludarabine | Tablet containing fludarabine phosphate 10 mg | Oral |
| Fludrocortisone | Tablet containing fludrocortisone acetate 100 micrograms | Oral |
| Fluorometholone | Eye drops 1 mg per mL, 5 mL | Application to the eye |
| Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL | Application to the eye | |
| Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral |
| Tablet, dispersible, 20 mg (as hydrochloride) | Oral | |
| Flupentixol decanoate | Oily I.M. injection 100 mg in 1 mL | Injection |
| Oily I.M. injection 20 mg in 1 mL | Injection | |
| Flutamide | Tablet 250 mg | Oral |
| Fluticasone furoate | Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms per dose, 30 doses | Inhalation by mouth |
| Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms per dose, 30 doses | Inhalation by mouth | |
| Fluticasone furoate with umeclidinium and vilanterol | Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | Inhalation by mouth |
| Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | Inhalation by mouth | |
| Fluticasone furoate with vilanterol | Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | Inhalation by mouth |
| Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | Inhalation by mouth | |
| Fluticasone propionate | Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms per dose, 60 doses | Inhalation by mouth |
| Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms per dose, 60 doses | Inhalation by mouth | |
| Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms per dose, 60 doses | Inhalation by mouth | |
| Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC‑free formulation) | Inhalation by mouth | |
| Pressurised inhalation containing fluticasone propionate 250 micrograms per dose, 120 doses (CFC‑free formulation) | Inhalation by mouth | |
| Pressurised inhalation containing fluticasone propionate 50 micrograms per dose, 120 doses (CFC‑free formulation) | Inhalation by mouth | |
| Fluticasone propionate with formoterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses | Inhalation by mouth |
| Pressurised inhalation containing fluticasone propionate 250 micrograms with formoterol fumarate dihydrate 10 micrograms per dose, 120 doses | Inhalation by mouth | |
| Pressurised inhalation containing fluticasone propionate 50 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses | Inhalation by mouth | |
| Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth |
| Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | |
| Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | |
| Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) | Inhalation by mouth | |
| Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) | Inhalation by mouth | |
| Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) | Inhalation by mouth | |
| Fluvastatin | Tablet (prolonged release) 80 mg (as sodium) | Oral |
| Fluvoxamine | Tablet containing fluvoxamine maleate 100 mg | Oral |
| Tablet containing fluvoxamine maleate 50 mg | Oral | |
| Folic acid | Tablet 5 mg | Oral |
| Tablet 500 micrograms | Oral | |
| Folinic acid | Injection containing calcium folinate equivalent to 100 mg folinic acid in 10 mL | Injection |
| Injection containing calcium folinate equivalent to 50 mg folinic acid in 5 mL | Injection | |
| Tablet containing calcium folinate equivalent to 15 mg folinic acid | Oral | |
| Follitropin alfa | Injection 150 I.U. in 0.25 mL pre‑filled pen | Injection |
| Injection 225 I.U. in 0.375 mL pre‑filled pen | Injection | |
| Injection 300 I.U. in 0.5 mL multi‑dose cartridge | Injection | |
| Injection 450 I.U. in 0.75 mL multi‑dose cartridge | Injection | |
| Injection 75 I.U. in 0.125 mL pre‑filled pen | Injection | |
| Injection 900 I.U. in 1.5 mL multi‑dose cartridge | Injection | |
| Follitropin beta | Solution for injection 300 I.U. in 0.36 mL multi‑dose cartridge | Injection |
| Solution for injection 600 I.U. in 0.72 mL multi‑dose cartridge | Injection | |
| Solution for injection 900 I.U. in 1.08 mL multi‑dose cartridge | Injection | |
| Fondaparinux | Injection containing fondaparinux sodium 2.5 mg in 0.5 mL single dose pre‑filled syringe | Injection |
| Formoterol | Capsule containing powder for oral inhalation containing formoterol fumarate dihydrate 12 micrograms (for use in Foradile Aerolizer) | Inhalation by mouth |
| Powder for oral inhalation in breath actuated device containing formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth | |
| Powder for oral inhalation in breath actuated device containing formoterol fumarate dihydrate 6 micrograms per dose, 60 doses | Inhalation by mouth | |
| Fosaprepitant | Powder for I.V. infusion 150 mg | Injection |
| Fosinopril | Tablet containing fosinopril sodium 10 mg | Oral |
| Tablet containing fosinopril sodium 20 mg | Oral | |
| Fosinopril with hydrochlorothiazide | Tablet containing fosinopril sodium 20 mg with hydrochlorothiazide 12.5 mg | Oral |
| Framycetin | Eye or ear drops containing framycetin sulfate 5 mg per mL, 8 mL | Application to the eye/ear |
| Fremanezumab | Solution for injection 225 mg in 1.5 mL single dose pre‑filled syringe | Injection |
| Fulvestrant | Injection 250 mg in 5 mL pre‑filled syringe | Injection |
| Furosemide | Injection 20 mg in 2 mL | Injection |
| Oral solution 10 mg per mL, 30 mL | Oral | |
| Tablet 20 mg | Oral | |
| Tablet 40 mg | Oral | |
| Tablet 500 mg | Oral | |
| Fusidic acid | Tablet containing sodium fusidate 250 mg | Oral |
| Gabapentin | Capsule 100 mg | Oral |
| Capsule 300 mg | Oral | |
| Capsule 400 mg | Oral | |
| Tablet 600 mg | Oral | |
| Tablet 800 mg | Oral | |
| Galantamine | Capsule (prolonged release) 16 mg (as hydrobromide) | Oral |
| Capsule (prolonged release) 24 mg (as hydrobromide) | Oral | |
| Capsule (prolonged release) 8 mg (as hydrobromide) | Oral | |
| Galcanezumab | Injection 120 mg in 1 mL pre‑filled pen | Injection |
| Gefitinib | Tablet 250 mg | Oral |
| Gemfibrozil | Tablet 600 mg | Oral |
| Gentamicin | Eye drops 3 mg (as sulfate) per mL, 5 mL | Application to the eye |
| Injection 80 mg (as sulfate) in 2 mL | Injection | |
| Glatiramer | Injection containing glatiramer acetate 40 mg in 1 mL single dose pre‑filled syringe | Injection |
| Glecaprevir with pibrentasvir | Tablet containing 100 mg glecaprevir with 40 mg pibrentasvir | Oral |
| Glibenclamide | Tablet 5 mg | Oral |
| Gliclazide | Tablet 30 mg (modified release) | Oral |
| Tablet 60 mg (modified release) | Oral | |
| Tablet 80 mg | Oral | |
| Glimepiride | Tablet 1 mg | Oral |
| Tablet 2 mg | Oral | |
| Tablet 3 mg | Oral | |
| Tablet 4 mg | Oral | |
| Glipizide | Tablet 5 mg | Oral |
| Glucagon | Injection set containing glucagon hydrochloride 1 mg (1 I.U.) and 1 mL solvent in disposable syringe | Injection |
| Glucose and ketone indicator‑urine | Test strips, 50 (Keto‑Diastix) | For external use |
| Glucose indicator‑urine | Test strips, 50 (Diastix) | For external use |
| Glyceryl trinitrate | Sublingual spray (pump pack) 400 micrograms per dose, 200 doses | Sublingual |
| Transdermal patch 18 mg | Transdermal | |
| Transdermal patch 25 mg | Transdermal | |
| Transdermal patch 36 mg | Transdermal | |
| Transdermal patch 50 mg | Transdermal | |
| Transdermal patch 54 mg | Transdermal | |
| Glycine with carbohydrate | Sachets of oral powder 4 g containing 500 mg glycine, 30 (Glycine500) | Oral |
| Glycomacropeptide and essential amino acid formula with vitamins, minerals, and low in tyrosine and phenylalanine | Sachets containing oral powder 31 g, 30 (Tylactin Build 20) | Oral |
| Sachets containing oral powder 35 g, 30 (TYR Sphere20) | Oral | |
| Glycomacropeptide and essential amino acids with vitamins and minerals | Bars 81 g, 14 (Tylactin Complete) | Oral |
| Bars 81 g, 7 (Camino Pro Complete) | Oral | |
| Oral liquid 250 mL, 30 (PKU Glytactin RTD 15 Lite) | Oral | |
| Oral liquid 250 mL, 30 (PKU Glytactin RTD 15) | Oral | |
| Oral liquid 250 mL, 30 (Tylactin RTD) | Oral | |
| Sachets containing oral powder 16 g, 60 (PKU Build 10) | Oral | |
| Sachets containing oral powder 20 g, 60 (PKU Restore) | Oral | |
| Sachets containing oral powder 32 g, 30 (PKU Build 20) | Oral | |
| Sachets containing oral powder 49 g, 30 (Camino Pro Bettermilk) | Oral | |
| Sachets containing oral powder 51 g, 30 (PKU Bettermilk Lite) | Oral | |
| Glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low in phenylalanine | Oral liquid 250 mL, 18 (PKU GMPro LQ) | Oral |
| Sachets containing oral powder 27 g, 30 (PKU Sphere15) | Oral | |
| Sachets containing oral powder 35 g, 30 (PKU Sphere20) | Oral | |
| Glycopyrronium | Capsule containing powder for oral inhalation 50 micrograms (as bromide) (for use in Breezhaler) | Inhalation by mouth |
| Golimumab | Injection 100 mg in 1 mL single use pre‑filled pen | Injection |
| Injection 50 mg in 0.5 mL single use pre‑filled pen | Injection | |
| Injection 50 mg in 0.5 mL single use pre‑filled syringe | Injection | |
| Goserelin | Subcutaneous implant (long acting) 10.8 mg (as acetate) in pre‑filled injection syringe | Implantation |
| Subcutaneous implant 3.6 mg (as acetate) in pre‑filled injection syringe | Implantation | |
| Goserelin and bicalutamide | Pack containing 1 subcutaneous implant containing goserelin 10.8 mg (as acetate) in pre‑filled injection syringe and 28 tablets bicalutamide 50 mg | Implantation/oral |
| Pack containing 1 subcutaneous implant containing goserelin 10.8 mg (as acetate) in pre‑filled injection syringe and 84 tablets bicalutamide 50 mg | Implantation/oral | |
| Pack containing 1 subcutaneous implant containing goserelin 3.6 mg (as acetate) in pre‑filled injection syringe and 28 tablets bicalutamide 50 mg | Implantation/oral | |
| Granisetron | Concentrated injection 3 mg (as hydrochloride) in 3 mL | Injection |
| Tablet 2 mg (as hydrochloride) | Oral | |
| Griseofulvin | Tablet 125 mg | Oral |
| Tablet 500 mg | Oral | |
| Guanfacine | Tablet 1 mg (as hydrochloride) | Oral |
| Tablet 2 mg (as hydrochloride) | Oral | |
| Tablet 3 mg (as hydrochloride) | Oral | |
| Tablet 4 mg (as hydrochloride) | Oral | |
| Guselkumab | Injection 100 mg in 1 mL single use pre‑filled pen | Injection |
| Injection 100 mg in 1 mL single use pre‑filled syringe | Injection | |
| Haloperidol | Injection 5 mg in 1 mL | Injection |
| Oral solution 2 mg per mL, 100 mL | Oral | |
| Tablet 1.5 mg | Oral | |
| Tablet 5 mg | Oral | |
| Tablet 500 micrograms | Oral | |
| Haloperidol decanoate | I.M. injection equivalent to 150 mg haloperidol in 3 mL ampoule | Injection |
| I.M. injection equivalent to 50 mg haloperidol in 1 mL ampoule | Injection | |
| Heparin | Injection (preservative‑free) 5,000 I.U. (as sodium) in 5 mL | Injection |
| Injection 5,000 units (as sodium) in 0.2 mL | Injection | |
| High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate | Oral liquid 200 mL, 32 (KetoCal 4:1 LQ) | Oral |
| Oral liquid 250 mL, 30 (KetoVie 3:1) | Oral | |
| Oral liquid 250 mL, 30 (KetoVie 4:1) | Oral | |
| Oral liquid 250 mL, 30 (KetoVie Peptide 4:1) | Oral | |
| Oral powder 300 g (KetoCal 3:1) | Oral | |
| Oral powder 300 g (KetoCal 4:1) | Oral | |
| Oral semi‑solid 100 g, 36 (K.Yo) | Oral | |
| Hyaluronic acid | Eye drops containing sodium hyaluronate 1 mg per mL, 10 mL | Application to the eye |
| Eye drops containing sodium hyaluronate 2 mg per mL, 10 mL | Application to the eye | |
| Hydralazine | Tablet containing hydralazine hydrochloride 25 mg | Oral |
| Tablet containing hydralazine hydrochloride 50 mg | Oral | |
| Hydrochlorothiazide | Tablet 25 mg | Oral |
| Hydrochlorothiazide with amiloride | Tablet containing hydrochlorothiazide 50 mg with amiloride hydrochloride 5 mg | Oral |
| Hydrocortisone | Cream containing hydrocortisone acetate 10 mg per g, 50 g | Application |
| Eye ointment containing hydrocortisone acetate 10 mg per g, 5 g | Application to the eye | |
| Injection 100 mg (as sodium succinate) with 2 mL solvent | Injection | |
| Injection 250 mg (as sodium succinate) with 2 mL solvent | Injection | |
| Ointment containing hydrocortisone acetate 10 mg per g, 50 g | Application | |
| Rectal foam containing hydrocortisone acetate 90 mg per applicatorful, 14 applications, aerosol 21.1 g | Rectal | |
| Tablet 20 mg | Oral | |
| Tablet 4 mg | Oral | |
| Hydromorphone | Injection containing hydromorphone hydrochloride 10 mg in 1 mL | Injection |
| Injection containing hydromorphone hydrochloride 2 mg in 1 mL | Injection | |
| Oral liquid containing hydromorphone hydrochloride 1 mg per mL, 200 mL | Oral | |
| Oral solution containing hydromorphone hydrochloride 1 mg per mL, 473 mL | Oral | |
| Tablet (modified release) containing hydromorphone hydrochloride 16 mg | Oral | |
| Tablet (modified release) containing hydromorphone hydrochloride 32 mg | Oral | |
| Tablet (modified release) containing hydromorphone hydrochloride 4 mg | Oral | |
| Tablet (modified release) containing hydromorphone hydrochloride 64 mg | Oral | |
| Tablet (modified release) containing hydromorphone hydrochloride 8 mg | Oral | |
| Tablet containing hydromorphone hydrochloride 2 mg | Oral | |
| Tablet containing hydromorphone hydrochloride 4 mg | Oral | |
| Tablet containing hydromorphone hydrochloride 8 mg | Oral | |
| Hydroxocobalamin | Injection 1 mg (as acetate) in 1 mL | Injection |
| Injection 1 mg (as chloride) in 1 mL | Injection | |
| Hydroxycarbamide | Capsule 500 mg | Oral |
| Hydroxychloroquine | Tablet containing hydroxychloroquine sulfate 200 mg | Oral |
| Hydroxyethyl starch 130/0.4 | I.V. infusion 30 g per 500 mL, 500 mL | Injection |
| Hyoscine | Injection containing hyoscine butylbromide 20 mg in 1 mL | Injection |
| Hypromellose | 0.3% w/v eye drops, 10 mL (preservative free) | Application to the eye |
| Eye drops 3 mg per mL, 10 mL | Application to the eye | |
| Eye drops 5 mg per mL, 15 mL | Application to the eye | |
| Hypromellose with carbomer 980 | Ocular lubricating gel 3 mg‑2 mg per g, 10 g | Application to the eye |
| Hypromellose with dextran | Eye drops containing 3 mg hypromellose 2900 with 1 mg dextran 70 per mL, single dose units 0.4 mL, 28 | Application to the eye |
| Eye drops containing 3 mg hypromellose 4500 with 1 mg dextran 70 per mL, 15 mL | Application to the eye | |
| Ibandronic acid | Tablet 50 mg (as ibandronate sodium monohydrate) | Oral |
| Ibrutinib | Capsule 140 mg | Oral |
| Ibuprofen | Tablet 400 mg | Oral |
| Icatibant | Injection 30 mg (as acetate) in 3 mL single use pre‑filled syringe | Injection |
| Idelalisib | Tablet 100 mg | Oral |
| Tablet 150 mg | Oral | |
| Imatinib | Capsule 100 mg (as mesilate) | Oral |
| Capsule 400 mg (as mesilate) | Oral | |
| Tablet 100 mg (as mesilate) | Oral | |
| Tablet 400 mg (as mesilate) | Oral | |
| Tablet 600 mg (as mesilate) | Oral | |
| Imipramine | Tablet containing imipramine hydrochloride 10 mg | Oral |
| Tablet containing imipramine hydrochloride 25 mg | Oral | |
| Imiquimod | Cream 50 mg per g, 2 g, 2 | Application |
| Cream 50 mg per g, 250 mg single use sachets, 12 | Application | |
| Indacaterol | Capsule containing powder for oral inhalation 150 micrograms (as maleate) (for use in Breezhaler) | Inhalation by mouth |
| Capsule containing powder for oral inhalation 300 micrograms (as maleate) (for use in Breezhaler) | Inhalation by mouth | |
| Indacaterol with glycopyrronium | Capsule containing powder for oral inhalation indacaterol 110 micrograms (as maleate) with glycopyrronium 50 micrograms (as bromide) (for use in Breezhaler) | Inhalation by mouth |
| Indacaterol with glycopyrronium and mometasone | Capsule containing powder for oral inhalation indacaterol 114 micrograms (as maleate) with glycopyrronium 46 micrograms (as bromide) and mometasone furoate 136 micrograms (for use in Breezhaler) |
| Indacaterol with glycopyrronium and mometasone | Capsule containing powder for oral inhalation indacaterol 114 micrograms (as maleate) with glycopyrronium 46 micrograms (as bromide) and mometasone furoate 68 micrograms (for use in Breezhaler) | Inhalation by mouth |
| Indacaterol with mometasone | Capsule containing powder for oral inhalation indacaterol 125 micrograms (as acetate) with mometasone furoate 62.5 micrograms (for use in Breezhaler) | Inhalation by mouth |
| Capsule containing powder for oral inhalation indacaterol 125 micrograms (as acetate) with mometasone furoate 127.5 micrograms (for use in Breezhaler) | Inhalation by mouth | |
| Capsule containing powder for oral inhalation indacaterol 125 micrograms (as acetate) with mometasone furoate 260 micrograms (for use in Breezhaler) | Inhalation by mouth | |
| Indapamide | Tablet containing indapamide hemihydrate 1.5 mg (sustained release) | Oral |
| Tablet containing indapamide hemihydrate 2.5 mg | Oral | |
| Indometacin | Capsule 25 mg | Oral |
| Suppository 100 mg | Rectal | |
| Infliximab | Solution for injection 120 mg in 1 mL pre‑filled pen | Injection |
| Solution for injection 120 mg in 1 mL pre‑filled syringe | Injection | |
| Insect allergen extract‑honey bee venom | Injection set containing 550 micrograms | Injection |
| Injection set containing 550 micrograms with diluent | Injection | |
| Insect allergen extract‑paper wasp venom | Injection set containing 550 micrograms | Injection |
| Injection set containing 550 micrograms with diluent | Injection | |
| Insect allergen extract‑yellow jacket venom | Injection set containing 550 micrograms | Injection |
| Injection set containing 550 micrograms with diluent | Injection | |
| Insulin aspart | Injection (human analogue) (fast acting) 100 units per mL, 10 mL vial | Injection |
| Injection (human analogue) 100 units per mL, 10 mL vial | Injection | |
| Injections (human analogue) (fast acting), pre‑filled pen, 100 units per mL, 3 mL, 5 | Injection | |
| Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5 | Injection | |
| Insulin aspart with insulin aspart protamine suspension | Injections (human analogue), cartridges, 30 units‑70 units per mL, 3 mL, 5 | Injection |
| Insulin degludec with insulin aspart | Injections, cartridges, 70 units‑30 units per mL, 3 mL, 5 | Injection |
| Injections, pre‑filled pen, 70 units‑30 units per mL, 3 mL, 5 | Injection | |
| Insulin detemir | Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5 | Injection |
| Insulin glargine | Injections (human analogue), cartridge, 300 units per mL, 1.5 mL, 3 | Injection |
| Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5 | Injection | |
| Injections (human analogue), cartridges, 300 units per mL, 1.5 mL, 5 | Injection | |
| Insulin glulisine | Injection (human analogue) 100 units per mL, 10 mL | Injection |
| Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5 | Injection | |
| Insulin isophane | Injection (human) 100 units per mL, 10 mL | Injection |
| Injections (human), cartridges, 100 units per mL, 3 mL, 5 | Injection | |
| Insulin lispro | Injection (human analogue) 100 units per mL, 10 mL vial | Injection |
| Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5 | Injection | |
| Injections (human analogue), pre‑filled pen, 200 units per mL, 3 mL, 5 | Injection | |
| Insulin lispro with insulin lispro protamine suspension | Injections (human analogue), cartridges, 25 units‑75 units per mL, 3 mL, 5 | Injection |
| Injections (human analogue), cartridges, 50 units‑50 units per mL, 3 mL, 5 | Injection | |
| Insulin neutral | Injection (human) 100 units per mL, 10 mL | Injection |
| Injections (human), cartridges, 100 units per mL, 3 mL, 5 | Injection | |
| Insulin neutral with insulin isophane | Injection (human) 30 units‑70 units per mL, 10 mL | Injection |
| Injections (human), cartridges, 30 units‑70 units per mL, 3 mL, 5 | Injection | |
| Injections (human), cartridges, 50 units‑50 units per mL, 3 mL, 5 | Injection | |
| Interferon beta‑1a | Injection 30 micrograms (6,000,000 I.U.) in 0.5 mL single dose pre‑filled syringe | Injection |
| Injection 44 micrograms (12,000,000 I.U.) in 0.5 mL single dose autoinjector | Injection | |
| Injection 44 micrograms (12,000,000 I.U.) in 0.5 mL single dose pre‑filled syringe | Injection | |
| Solution for injection 132 micrograms in 1.5 mL multidose cartridge | Injection | |
| Interferon beta‑1b | Injection set including 1 vial powder for injection 8,000,000 I.U. (250 micrograms) and solvent | Injection |
| Ipratropium | Nebuliser solution containing ipratropium bromide 250 micrograms (as monohydrate) in 1 mL single dose units, 30 | Inhalation |
| Nebuliser solution containing ipratropium bromide 500 micrograms (as monohydrate) in 1 mL single dose units, 30 | Inhalation | |
| Pressurised inhalation containing ipratropium bromide monohydrate 21 micrograms per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth | |
| Irbesartan | Tablet 150 mg | Oral |
| Tablet 300 mg | Oral | |
| Tablet 75 mg | Oral | |
| Irbesartan with hydrochlorothiazide | Tablet 150 mg‑12.5 mg | Oral |
| Tablet 300 mg‑12.5 mg | Oral | |
| Tablet 300 mg‑25 mg | Oral | |
| Iron polymaltose complex | Injection 100 mg (iron) in 2 mL | Injection |
| Iron sucrose | Concentrate for solution for infusion 2.7 g (equivalent to 100 mg iron (III)) in 5 mL | Injection |
| Isoleucine with carbohydrate | Sachets of oral powder 4 g containing 1 g isoleucine, 30 (Isoleucine 1000) | Oral |
| Sachets of oral powder 4 g containing 50 mg isoleucine, 30 (Isoleucine 50) | Oral | |
| Isoniazid | Tablet 100 mg | Oral |
| Isosorbide dinitrate | Tablet 5 mg (sublingual) | Oral |
| Isosorbide mononitrate | Tablet 120 mg (sustained release) | Oral |
| Tablet 60 mg (sustained release) | Oral | |
| Isotretinoin | Capsule 10 mg | Oral |
| Capsule 20 mg | Oral | |
| Capsule 30 mg | Oral | |
| Capsule 40 mg | Oral | |
| Capsule 5 mg | Oral | |
| Itraconazole | Capsule 100 mg | Oral |
| Capsule 50 mg | Oral | |
| Ivabradine | Tablet 5 mg (as hydrochloride) | Oral |
| Tablet 7.5 mg (as hydrochloride) | Oral | |
| Ivermectin | Tablet 3 mg | Oral |
| Ixekizumab | Injection 80 mg in 1 mL single dose pre‑filled pen | Injection |
| Ketoconazole | Cream 20 mg per g, 30 g | Application |
| Shampoo 20 mg per g, 60 mL | Application | |
| Ketoprofen | Capsule 200 mg (sustained release) | Oral |
| Labetalol | Tablet containing labetalol hydrochloride 100 mg | Oral |
| Tablet containing labetalol hydrochloride 200 mg | Oral | |
| Lacosamide | Oral solution 10 mg per mL, 200 mL | Oral |
| Tablet 100 mg | Oral | |
| Tablet 150 mg | Oral | |
| Tablet 200 mg | Oral | |
| Tablet 50 mg | Oral | |
| Lamotrigine | Tablet 100 mg | Oral |
| Tablet 200 mg | Oral | |
| Tablet 25 mg | Oral | |
| Tablet 5 mg | Oral | |
| Tablet 50 mg | Oral | |
| Lanadelumab | Injection 300 mg in 2 mL single use pre‑filled syringe | Injection |
| Lansoprazole | Capsule 15 mg | Oral |
| Capsule 30 mg | Oral | |
| Tablet 15 mg (orally disintegrating) | Oral | |
| Tablet 30 mg (orally disintegrating) | Oral | |
| Lanthanum | Tablet, chewable, 1000 mg (as carbonate hydrate) | Oral |
| Tablet, chewable, 500 mg (as carbonate hydrate) | Oral | |
| Tablet, chewable, 750 mg (as carbonate hydrate) | Oral | |
| Lapatinib | Tablet 250 mg (as ditosilate monohydrate) | Oral |
| Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | Application to the eye |
| Latanoprost with timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the eye |
| Ledipasvir with sofosbuvir | Tablet containing 90 mg ledipasvir with 400 mg sofosbuvir | Oral |
| Leflunomide | Tablet 10 mg | Oral |
| Tablet 20 mg | Oral | |
| Lenvatinib | Capsule 10 mg (as mesilate) | Oral |
| Capsule 4 mg (as mesilate) | Oral | |
| Lercanidipine | Tablet containing lercanidipine hydrochloride 10 mg | Oral |
| Tablet containing lercanidipine hydrochloride 20 mg | Oral | |
| Lercanidipine with enalapril | Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 10 mg | Oral |
| Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 20 mg | Oral | |
| Letrozole | Tablet 2.5 mg | Oral |
| Leuprorelin | I.M. injection (3 month modified release), powder for injection containing leuprorelin acetate 30 mg with diluent in pre‑filled dual‑chamber syringe | Injection |
| I.M. injection (modified release), powder for injection containing leuprorelin acetate 22.5 mg with diluent in pre‑filled dual‑chamber syringe | Injection | |
| I.M. injection (modified release), powder for injection containing leuprorelin acetate 30 mg with diluent in pre‑filled dual‑chamber syringe | Injection | |
| I.M. injection (modified release), powder for injection containing leuprorelin acetate 45 mg with diluent in pre‑filled dual‑chamber syringe | Injection | |
| I.M. injection (modified release), powder for injection containing leuprorelin acetate 7.5 mg with diluent in pre‑filled dual‑chamber syringe | Injection | |
| Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 22.5 mg, injection set | Injection | |
| Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 30 mg, injection set | Injection | |
| Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 45 mg, injection set | Injection | |
| Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 7.5 mg, injection set | Injection | |
| Leuprorelin and bicalutamide | Pack containing 1 syringe containing leuprorelin 22.5 mg (as acetate) and 28 tablets bicalutamide 50 mg | Injection/oral |
| Pack containing 1 syringe containing leuprorelin 22.5 mg (as acetate) and 84 tablets bicalutamide 50 mg | Injection/oral | |
| Pack containing 1 syringe containing leuprorelin 7.5 mg (as acetate) and 28 tablets bicalutamide 50 mg | Injection/oral | |
| Levetiracetam | Oral solution 100 mg per mL, 300 mL | Oral |
| Tablet 1 g | Oral | |
| Tablet 250 mg | Oral | |
| Tablet 500 mg | Oral | |
| Levodopa with benserazide | Capsule containing levodopa 100 mg with 25 mg benserazide (as hydrochloride) | Oral |
| Capsule containing levodopa 100 mg with 25 mg benserazide (as hydrochloride) (sustained release) | Oral | |
| Capsule containing levodopa 200 mg with 50 mg benserazide (as hydrochloride) | Oral | |
| Capsule containing levodopa 50 mg with 12.5 mg benserazide (as hydrochloride) | Oral | |
| Dispersible tablet containing levodopa 100 mg with 25 mg benserazide (as hydrochloride) | Oral | |
| Dispersible tablet containing levodopa 50 mg with 12.5 mg benserazide (as hydrochloride) | Oral | |
| Tablet containing levodopa 100 mg with 25 mg benserazide (as hydrochloride) | Oral | |
| Tablet containing levodopa 200 mg with 50 mg benserazide (as hydrochloride) | Oral | |
| Levodopa with carbidopa | Intestinal gel containing levodopa 20 mg with carbidopa monohydrate 5 mg per mL, 100 mL | Intra‑intestinal |
| Tablet (modified release) 200 mg‑50 mg (as monohydrate) | Oral | |
| Tablet (prolonged release) 200 mg‑50 mg | Oral | |
| Tablet 100 mg‑25 mg (as monohydrate) | Oral | |
| Tablet 250 mg‑25 mg (as monohydrate) | Oral | |
| Levodopa with carbidopa and entacapone | Tablet 100 mg‑25 mg (as monohydrate)‑200 mg | Oral |
| Tablet 125 mg‑31.25 mg (as monohydrate)‑200 mg | Oral | |
| Tablet 150 mg‑37.5 mg (as monohydrate)‑200 mg | Oral | |
| Tablet 200 mg‑50 mg (as monohydrate)‑200 mg | Oral | |
| Tablet 50 mg‑12.5 mg (as monohydrate)‑200 mg | Oral | |
| Tablet 75 mg‑18.75 mg (as monohydrate)‑200 mg | Oral | |
| Levonorgestrel | Intrauterine drug delivery system 19.5 mg | Intrauterine |
| Intrauterine drug delivery system 52 mg | intrauterine | |
| Tablets 30 micrograms, 28 | Oral | |
| Levonorgestrel with ethinylestradiol | Pack containing 21 tablets 100 micrograms‑20 micrograms and 7 inert tablets | Oral |
| Pack containing 21 tablets 125 micrograms‑50 micrograms and 7 inert tablets | Oral | |
| Pack containing 21 tablets 150 micrograms‑30 micrograms and 7 inert tablets | Oral | |
| Pack containing 6 tablets 50 micrograms‑30 micrograms, 5 tablets 75 micrograms‑40 micrograms, 10 tablets 125 micrograms‑30 micrograms and 7 inert tablets | Oral | |
| Levothyroxine | Tablet containing 100 micrograms anhydrous levothyroxine sodium | Oral |
| Tablet containing 125 micrograms anhydrous levothyroxine sodium | Oral | |
| Tablet containing 200 micrograms anhydrous levothyroxine sodium | Oral | |
| Tablet containing 50 micrograms anhydrous levothyroxine sodium | Oral | |
| Tablet containing 75 micrograms anhydrous levothyroxine sodium | Oral | |
| Lidocaine | Infusion containing lidocaine hydrochloride 500 mg in 5 mL | Injection |
| Linagliptin | Tablet 5 mg | Oral |
| Linagliptin with metformin | Tablet containing 2.5 mg linagliptin with 1000 mg metformin hydrochloride | Oral |
| Tablet containing 2.5 mg linagliptin with 500 mg metformin hydrochloride | Oral | |
| Tablet containing 2.5 mg linagliptin with 850 mg metformin hydrochloride | Oral | |
| Lincomycin | Injection 600 mg (as hydrochloride monohydrate) in 2 mL | Injection |
| Liothyronine | Tablet containing liothyronine sodium 20 micrograms | Oral |
| Lisdexamfetamine | Capsule containing lisdexamfetamine dimesilate 20 mg | Oral |
| Capsule containing lisdexamfetamine dimesilate 30 mg | Oral | |
| Capsule containing lisdexamfetamine dimesilate 40 mg | Oral | |
| Capsule containing lisdexamfetamine dimesilate 50 mg | Oral | |
| Capsule containing lisdexamfetamine dimesilate 60 mg | Oral | |
| Capsule containing lisdexamfetamine dimesilate 70 mg | Oral | |
| Lisinopril | Tablet 10 mg | Oral |
| Tablet 20 mg | Oral | |
| Tablet 5 mg | Oral | |
| Lithium | Tablet containing lithium carbonate 250 mg | Oral |
| Tablet containing lithium carbonate 450 mg (slow release) | Oral | |
| Loperamide | Capsule containing loperamide hydrochloride 2 mg | Oral |
| Lorlatinib | Tablet 25 mg | Oral |
| Tablet 100 mg | Oral | |
| Losartan | Tablet containing losartan potassium 25 mg | Oral |
| Tablet containing losartan potassium 50 mg | Oral | |
| Lurasidone | Tablet containing lurasidone hydrochloride 40 mg | Oral |
| Tablet containing lurasidone hydrochloride 80 mg | Oral | |
| Macrogol 3350 | Oral liquid 13.125 g in 25 mL with electrolytes, 500 mL | Oral |
| Powder for oral solution 510 g | Oral | |
| Sachets containing powder for oral solution 13.125 g with electrolytes, 30 | Oral | |
| Magnesium | Tablet 37.4 mg (as aspartate dihydrate) | Oral |
| Medroxyprogesterone | Injection containing medroxyprogesterone acetate 150 mg in 1 mL | Injection |
| Tablet containing medroxyprogesterone acetate 10 mg | Oral | |
| Tablet containing medroxyprogesterone acetate 100 mg | Oral | |
| Tablet containing medroxyprogesterone acetate 200 mg | Oral | |
| Tablet containing medroxyprogesterone acetate 250 mg | Oral | |
| Tablet containing medroxyprogesterone acetate 5 mg | Oral | |
| Tablet containing medroxyprogesterone acetate 500 mg | Oral | |
| Mefenamic acid | Capsule 250 mg | Oral |
| Meloxicam | Capsule 15 mg | Oral |
| Capsule 7.5 mg | Oral | |
| Tablet 15 mg | Oral | |
| Tablet 7.5 mg | Oral | |
| Melphalan | Tablet 2 mg | Oral |
| Memantine | Tablet containing memantine hydrochloride 10 mg | Oral |
| Tablet containing memantine hydrochloride 20 mg | Oral | |
| Mercaptopurine | Oral suspension containing mercaptopurine monohydrate 20 mg per mL, 100 mL | Oral |
| Tablet containing mercaptopurine monohydrate 50 mg | Oral | |
| Mesalazine | Enemas 1 g in 100 mL, 7 | Rectal |
| Enemas 2 g in 60 mL, 7 | Rectal | |
| Enemas 4 g in 60 mL, 7 | Rectal | |
| Rectal foam 1 g per applicatorful, 14 applications, aerosol 80 g | Rectal | |
| Sachet containing granules, 500 mg per sachet | Oral | |
| Sachet containing granules, 1 g per sachet | Oral | |
| Sachet containing granules, 1.5 g per sachet | Oral | |
| Sachet containing granules, 3 g per sachet | Oral | |
| Sachet containing prolonged release granules, 1 g per sachet | Oral | |
| Sachet containing prolonged release granules, 2 g per sachet | Oral | |
| Sachet containing prolonged release granules, 4 g per sachet | Oral | |
| Suppository 1 g | Rectal | |
| Suppository (moulded) 1 g | Rectal | |
| Tablet 250 mg (enteric coated) | Oral | |
| Tablet 500 mg (enteric coated) | Oral | |
| Tablet 500 mg (prolonged release) | Oral | |
| Tablet 800 mg (enteric coated) | Oral | |
| Tablet 1 g (enteric coated) | Oral | |
| Tablet 1 g (prolonged release) | Oral | |
| Tablet 1.2 g (prolonged release) | Oral | |
| Tablet 1.6 g (enteric coated) | Oral | |
| Mesna | Solution for I.V. injection 1 g in 10 mL ampoule | Injection |
| Solution for I.V. injection 400 mg in 4 mL ampoule | Injection | |
| Metformin | Tablet containing metformin hydrochloride 500 mg | Oral |
| Tablet containing metformin hydrochloride 850 mg | Oral | |
| Tablet containing metformin hydrochloride 1 g | Oral | |
| Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | |
| Tablet (extended release) containing metformin hydrochloride 1 g | Oral | |
| Methadone | Injection containing methadone hydrochloride 10 mg in 1 mL | Injection |
| Oral liquid containing methadone hydrochloride 25 mg per 5 mL, 200 mL | Oral | |
| Tablet containing methadone hydrochloride 10 mg | Oral | |
| Methenamine | Tablet containing methenamine hippurate 1 g | Oral |
| Methotrexate | Injection 7.5 mg in 0.15 mL pre‑filled syringe | Injection |
| Injection 10 mg in 0.2 mL pre‑filled syringe | Injection | |
| Injection 15 mg in 0.3 mL pre‑filled syringe | Injection | |
| Injection 20 mg in 0.4 mL pre‑filled syringe | Injection | |
| Injection 25 mg in 0.5 mL pre‑filled syringe | Injection | |
| Injection 5 mg in 2 mL vial | Injection | |
| Injection 50 mg in 2 mL vial | Injection | |
| Tablet 2.5 mg | Oral | |
| Tablet 10 mg | Oral | |
| Methyldopa | Tablet 250 mg (as sesquihydrate) | Oral |
| Methylnaltrexone | Solution for injection containing methylnaltrexone bromide 12 mg in 0.6 mL | Injection |
| Methylphenidate | Capsule containing methylphenidate hydrochloride 10 mg (modified release) | Oral |
| Capsule containing methylphenidate hydrochloride 20 mg (modified release) | Oral | |
| Capsule containing methylphenidate hydrochloride 30 mg (modified release) | Oral | |
| Capsule containing methylphenidate hydrochloride 40 mg (modified release) | Oral | |
| Capsule containing methylphenidate hydrochloride 60 mg (modified release) | Oral | |
| Tablet containing methylphenidate hydrochloride 10 mg | Oral | |
| Tablet containing methylphenidate hydrochloride 18 mg (extended release) | Oral | |
| Tablet containing methylphenidate hydrochloride 27 mg (extended release) | Oral | |
| Tablet containing methylphenidate hydrochloride 36 mg (extended release) | Oral | |
| Tablet containing methylphenidate hydrochloride 54 mg (extended release) | Oral | |
| Methylprednisolone | Cream containing methylprednisolone aceponate 1 mg per g, 15 g | Application |
| Fatty ointment containing methylprednisolone aceponate 1 mg per g, 15 g | Application | |
| Injection containing methylprednisolone acetate 40 mg in 1 mL | Injection | |
| Lotion containing methylprednisolone aceponate 1 mg per g, 20 g | Application | |
| Ointment containing methylprednisolone aceponate 1 mg per g, 15 g | Application | |
| Powder for injection 1 g (as sodium succinate) | Injection | |
| Powder for injection 40 mg (as sodium succinate) | Injection | |
| Powder for injection 40 mg (as sodium succinate) with diluent | Injection | |
| Metoclopramide | Injection containing 10 mg metoclopramide hydrochloride (as monohydrate) in 2 mL | Injection |
| Tablet containing 10 mg metoclopramide hydrochloride (as monohydrate) | Oral | |
| Metoprolol | Tablet containing metoprolol tartrate 100 mg | Oral |
| Tablet containing metoprolol tartrate 50 mg | Oral | |
| Metoprolol succinate | Tablet 190 mg (controlled release) | Oral |
| Tablet 23.75 mg (controlled release) | Oral | |
| Tablet 47.5 mg (controlled release) | Oral | |
| Tablet 95 mg (controlled release) | Oral | |
| Metronidazole | Oral suspension containing metronidazole benzoate 320 mg per 5 mL, 100 mL | Oral |
| Suppositories 500 mg, 10 | Rectal | |
| Tablet 200 mg | Oral | |
| Tablet 400 mg | Oral | |
| Mianserin | Tablet containing mianserin hydrochloride 10 mg | Oral |
| Tablet containing mianserin hydrochloride 20 mg | Oral | |
| Miconazole | Cream containing miconazole nitrate 20 mg per g, 30 g | Application |
| Cream containing miconazole nitrate 20 mg per g, 70 g | Application | |
| Powder containing miconazole nitrate 20 mg per g, 30 g | Application | |
| Tincture 20 mg per mL, 30 mL | Application | |
| Mifepristone and misoprostol | Pack containing 1 tablet mifepristone 200 mg and 4 tablets misoprostol 200 micrograms | Oral |
| Milk powder ‑‑ synthetic | Low calcium oral powder 400 g (Locasol) | Oral |
| Milk protein and fat formula with vitamins and minerals ‑‑ carbohydrate free | Oral powder 225 g (Carbohydrate Free Mixture) | Oral |
| Minocycline | Tablet 50 mg (as hydrochloride) | Oral |
| Minoxidil | Tablet 10 mg | Oral |
| Mirtazapine | Tablet 15 mg | Oral |
| Tablet 15 mg (orally disintegrating) | Oral | |
| Tablet 30 mg | Oral | |
| Tablet 30 mg (orally disintegrating) | Oral | |
| Tablet 45 mg | Oral | |
| Tablet 45 mg (orally disintegrating) | Oral | |
| Moclobemide | Tablet 150 mg | Oral |
| Tablet 300 mg | Oral | |
| Modafinil | Tablet 100 mg | Oral |
| Mometasone | Cream containing mometasone furoate 1 mg per g, 15 g | Application |
| Lotion containing mometasone furoate 1 mg per g, 30 mL | Application | |
| Ointment containing mometasone furoate 1 mg per g, 15 g | Application | |
| Montelukast | Tablet, chewable, 4 mg (as sodium) | Oral |
| Tablet, chewable, 5 mg (as sodium) | Oral | |
| Morphine | Capsule containing morphine sulfate pentahydrate 10 mg (containing sustained release pellets) | Oral |
| Capsule containing morphine sulfate pentahydrate 100 mg (containing sustained release pellets) | Oral | |
| Capsule containing morphine sulfate pentahydrate 120 mg (controlled release) | Oral | |
| Capsule containing morphine sulfate pentahydrate 20 mg (containing sustained release pellets) | Oral | |
| Capsule containing morphine sulfate pentahydrate 30 mg (controlled release) | Oral | |
| Capsule containing morphine sulfate pentahydrate 50 mg (containing sustained release pellets) | Oral | |
| Capsule containing morphine sulfate pentahydrate 60 mg (controlled release) | Oral | |
| Capsule containing morphine sulfate pentahydrate 90 mg (controlled release) | Oral | |
| Injection containing morphine hydrochloride trihydrate 10 mg in 1 mL | Injection | |
| Injection containing morphine hydrochloride trihydrate 100 mg in 5 mL | Injection | |
| Injection containing morphine hydrochloride trihydrate 20 mg in 1 mL | Injection | |
| Injection containing morphine hydrochloride trihydrate 50 mg in 5 mL | Injection | |
| Injection containing morphine sulfate pentahydrate 10 mg in 1 mL | Injection | |
| Injection containing morphine sulfate pentahydrate 15 mg in 1 mL | Injection | |
| Injection containing morphine sulfate pentahydrate 30 mg in 1 mL | Injection | |
| Oral solution containing morphine hydrochloride trihydrate 10 mg per mL, 200 mL | Oral | |
| Oral solution containing morphine hydrochloride trihydrate 2 mg per mL, 200 mL | Oral | |
| Oral solution containing morphine hydrochloride trihydrate 5 mg per mL, 200 mL | Oral | |
| Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 100 mg per sachet | Oral | |
| Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 20 mg per sachet | Oral | |
| Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 200 mg per sachet | Oral | |
| Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 30 mg per sachet | Oral | |
| Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 60 mg per sachet | Oral | |
| Tablet containing morphine sulfate pentahydrate 10 mg | Oral | |
| Tablet containing morphine sulfate pentahydrate 10 mg (controlled release) | Oral | |
| Tablet containing morphine sulfate pentahydrate 100 mg (controlled release) | Oral | |
| Tablet containing morphine sulfate pentahydrate 15 mg (controlled release) | Oral | |
| Tablet containing morphine sulfate pentahydrate 20 mg | Oral | |
| Tablet containing morphine sulfate pentahydrate 200 mg (controlled release) | Oral | |
| Tablet containing morphine sulfate pentahydrate 30 mg | Oral | |
| Tablet containing morphine sulfate pentahydrate 30 mg (controlled release) | Oral | |
| Tablet containing morphine sulfate pentahydrate 5 mg (controlled release) | Oral | |
| Tablet containing morphine sulfate pentahydrate 60 mg (controlled release) | Oral | |
| Moxonidine | Tablet 200 micrograms | Oral |
| Tablet 400 micrograms | Oral | |
| Mupirocin | Nasal ointment 20 mg (as calcium) per g, 3 g | Nasal |
| Nasal ointment 20 mg (as calcium) per g, 5 g | Nasal | |
| Mycobacterium bovis (Bacillus Calmette and Guerin (BCG)) Danish 1331 strain | Single dose pack containing powder for irrigation 30 mg, 4 vials | Intravesical |
| Mycobacterium bovis (Bacillus Calmette and Guerin), Tice strain | Vial containing powder for intravesical administration approximately 5 x 10<sup>8</sup> CFU | Intravesical |
| Mycophenolic acid | Capsule containing mycophenolate mofetil 250 mg | Oral |
| Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL | Oral | |
| Tablet (enteric coated) containing mycophenolate sodium equivalent to 180 mg mycophenolic acid | Oral | |
| Tablet (enteric coated) containing mycophenolate sodium equivalent to 360 mg mycophenolic acid | Oral | |
| Tablet containing mycophenolate mofetil 500 mg | Oral | |
| Nafarelin | Nasal spray (pump pack) 200 micrograms (as acetate) per dose, 60 doses | Nasal |
| Naloxone | Injection containing naloxone hydrochloride 2 mg in 2 mL pre‑filled syringe | Injection |
| Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule | Injection | |
| Nasal spray 1.8 mg (as hydrochloride dihydrate) in 0.1 mL single dose unit, 2 | Nasal | |
| Naltrexone | Tablet containing naltrexone hydrochloride 50 mg | Oral |
| Naproxen | Oral suspension 125 mg per 5 mL, 474 mL | Oral |
| Tablet 1 g (sustained release) | Oral | |
| Tablet 250 mg | Oral | |
| Tablet 750 mg (sustained release) | Oral | |
| Tablet containing naproxen sodium 550 mg | Oral | |
| Naratriptan | Tablet 2.5 mg (as hydrochloride) | Oral |
| Nebivolol | Tablet 1.25 mg (as hydrochloride) | Oral |
| Tablet 10 mg (as hydrochloride) | Oral | |
| Tablet 5 mg (as hydrochloride) | Oral | |
| Netupitant with Palonosetron | Capsule containing netupitant 300 mg with palonosetron 500 microgram (as hydrochloride) | Oral |
| Nicorandil | Tablets 10 mg, 60 | Oral |
| Tablets 20 mg, 60 | Oral | |
| Nicotine | Gum 2 mg | Buccal |
| Gum 4 mg | Buccal | |
| Lozenge 2 mg | Buccal | |
| Lozenge 4 mg | Buccal | |
| Transdermal patch 114 mg | Transdermal | |
| Transdermal patch 17.5 mg | Transdermal | |
| Transdermal patch 35 mg | Transdermal | |
| Transdermal patch 39.4 mg | Transdermal | |
| Transdermal patch 52.5 mg | Transdermal | |
| Nifedipine | Tablet 10 mg | Oral |
| Tablet 20 mg | Oral | |
| Tablet 30 mg (controlled release) | Oral | |
| Tablet 60 mg (controlled release) | Oral | |
| Nilotinib | Capsule 150 mg (as hydrochloride monohydrate) | Oral |
| Capsule 200 mg (as hydrochloride monohydrate) | Oral | |
| Nintedanib | Capsule 100 mg | Oral |
| Capsule 150 mg | Oral | |
| Nitrazepam | Tablet 5 mg | Oral |
| Nitrofurantoin | Capsule 50 mg | Oral |
| Capsule 50 mg, USP | Oral | |
| Capsule 100 mg | Oral | |
| Nizatidine | Capsule 150 mg | Oral |
| Capsule 300 mg | Oral | |
| Norethisterone | Tablet 5 mg | Oral |
| Tablets 350 micrograms, 28 | Oral | |
| Norethisterone with ethinylestradiol | Pack containing 21 tablets 1 mg‑35 micrograms and 7 inert tablets | Oral |
| Pack containing 21 tablets 500 micrograms‑35 micrograms and 7 inert tablets | Oral | |
| Norethisterone with mestranol | Pack containing 21 tablets 1 mg‑50 micrograms and 7 inert tablets | Oral |
| Norfloxacin | Tablet 400 mg | Oral |
| Nortriptyline | Tablet 10 mg (as hydrochloride) | Oral |
| Tablet 25 mg (as hydrochloride) | Oral | |
| Nystatin | Capsule 500,000 units | Oral |
| Tablet 500,000 units | Oral | |
| Obeticholic acid | Tablet 5 mg | Oral |
| Tablet 10 mg | Oral | |
| Ocriplasmin | Solution for intravitreal injection 0.375 mg in 0.3 mL | Injection |
| Ofatumumab | Solution for injection 20 mg in 0.4 mL pre‑filled pen | Injection |
| Ofloxacin | Eye drops 3 mg per mL, 5 mL | Application to the eye |
| Olanzapine | Powder for injection 210 mg (as pamoate monohydrate) with diluent | Injection |
| Powder for injection 300 mg (as pamoate monohydrate) with diluent | Injection | |
| Powder for injection 405 mg (as pamoate monohydrate) with diluent | Injection | |
| Tablet 10 mg | Oral | |
| Tablet 10 mg (orally disintegrating) | Oral | |
| Tablet 15 mg (orally disintegrating) | Oral | |
| Tablet 2.5 mg | Oral | |
| Tablet 20 mg (orally disintegrating) | Oral | |
| Tablet 5 mg | Oral | |
| Tablet 5 mg (orally disintegrating) | Oral | |
| Tablet 7.5 mg | Oral | |
| Wafer 10 mg | Oral | |
| Wafer 15 mg | Oral | |
| Wafer 20 mg | Oral | |
| Wafer 5 mg | Oral | |
| Olaparib | Tablet 100 mg | Oral |
| Tablet 150 mg | Oral | |
| Olmesartan | Tablet containing olmesartan medoxomil 20 mg | Oral |
| Tablet containing olmesartan medoxomil 40 mg | Oral | |
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) | Oral |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) | Oral | |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) | Oral | |
| Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg | Oral |
| Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg | Oral | |
| Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg | Oral | |
| Olsalazine | Capsule containing olsalazine sodium 250 mg | Oral |
| Tablet containing olsalazine sodium 500 mg | Oral | |
| Omeprazole | Capsule 20 mg | Oral |
| Tablet 10 mg (as magnesium) | Oral | |
| Tablet 20 mg | Oral | |
| Tablet 20 mg (as magnesium) | Oral | |
| Ondansetron | Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL | Oral |
| Tablet (orally disintegrating) 4 mg | Oral | |
| Tablet (orally disintegrating) 8 mg | Oral | |
| Tablet 4 mg (as hydrochloride dihydrate) | Oral | |
| Tablet 8 mg (as hydrochloride dihydrate) | Oral | |
| Wafer 4 mg | Oral | |
| Wafer 8 mg | Oral | |
| Osimertinib | Tablet 40 mg | Oral |
| Tablet 80 mg | Oral | |
| Oxazepam | Tablet 15 mg | Oral |
| Tablet 30 mg | Oral | |
| Oxcarbazepine | Oral suspension 60 mg per mL, 250 mL | Oral |
| Tablet 150 mg | Oral | |
| Tablet 300 mg | Oral | |
| Tablet 600 mg | Oral | |
| Oxprenolol | Tablet containing oxprenolol hydrochloride 40 mg | Oral |
| Oxybutynin | Tablet containing oxybutynin hydrochloride 5 mg | Oral |
| Transdermal patches 36 mg, 8 | Transdermal | |
| Oxycodone | Capsule containing oxycodone hydrochloride 10 mg | Oral |
| Capsule containing oxycodone hydrochloride 20 mg | Oral | |
| Capsule containing oxycodone hydrochloride 5 mg | Oral | |
| Oral solution containing oxycodone hydrochloride 1 mg per mL, 250 mL | Oral | |
| Suppository 30 mg (as pectinate) | Rectal | |
| Tablet containing oxycodone hydrochloride 10 mg (controlled release) | Oral | |
| Tablet containing oxycodone hydrochloride 15 mg (controlled release) | Oral | |
| Tablet containing oxycodone hydrochloride 20 mg (controlled release) | Oral | |
| Tablet containing oxycodone hydrochloride 30 mg (controlled release) | Oral | |
| Tablet containing oxycodone hydrochloride 40 mg (controlled release) | Oral | |
| Tablet containing oxycodone hydrochloride 5 mg | Oral | |
| Tablet containing oxycodone hydrochloride 80 mg (controlled release) | Oral | |
| Oxycodone with naloxone | Tablet (controlled release) containing oxycodone hydrochloride 10 mg with naloxone hydrochloride 5 mg | Oral |
| Tablet (controlled release) containing oxycodone hydrochloride 15 mg with naloxone hydrochloride 7.5 mg | Oral | |
| Tablet (controlled release) containing oxycodone hydrochloride 2.5 mg with naloxone hydrochloride 1.25 mg | Oral | |
| Tablet (controlled release) containing oxycodone hydrochloride 20 mg with naloxone hydrochloride 10 mg | Oral | |
| Tablet (controlled release) containing oxycodone hydrochloride 30 mg with naloxone hydrochloride 15 mg | Oral | |
| Tablet (controlled release) containing oxycodone hydrochloride 40 mg with naloxone hydrochloride 20 mg | Oral | |
| Tablet (controlled release) containing oxycodone hydrochloride 5 mg with naloxone hydrochloride 2.5 mg | Oral | |
| Tablet (controlled release) containing oxycodone hydrochloride 60 mg with naloxone hydrochloride 30 mg | Oral | |
| Tablet (controlled release) containing oxycodone hydrochloride 80 mg with naloxone hydrochloride 40 mg | Oral | |
| Ozanimod | Capsule 920 micrograms | Oral |
| Pack containing 4 capsules 230 micrograms and 3 capsules 460 micrograms | Oral | |
| Palbociclib | Tablet 75 mg | Oral |
| Tablet 100 mg | Oral | |
| Tablet 125 mg | Oral | |
| Paliperidone | I.M. injection (modified release) 100 mg (as palmitate) in pre‑filled syringe | Injection |
| I.M. injection (modified release) 150 mg (as palmitate) in pre‑filled syringe | Injection | |
| I.M. injection (modified release) 175 mg (as palmitate) in pre‑filled syringe | Injection | |
| I.M. injection (modified release) 25 mg (as palmitate) in pre‑filled syringe | Injection | |
| I.M. injection (modified release) 263 mg (as palmitate) in pre‑filled syringe | Injection | |
| I.M. injection (modified release) 350 mg (as palmitate) in pre‑filled syringe | Injection | |
| I.M. injection (modified release) 50 mg (as palmitate) in pre‑filled syringe | Injection | |
| I.M. injection (modified release) 525 mg (as palmitate) in pre‑filled syringe | Injection | |
| I.M. injection (modified release) 75 mg (as palmitate) in pre‑filled syringe | Injection | |
| Tablet 3 mg (prolonged release) | Oral | |
| Tablet 6 mg (prolonged release) | Oral | |
| Tablet 9 mg (prolonged release) | Oral | |
| Palonosetron | Injection 250 micrograms (as hydrochloride) in 5 mL | Injection |
| Pamidronic acid | Concentrated injection containing pamidronate disodium 15 mg in 5 mL | Injection |
| Concentrated injection containing pamidronate disodium 30 mg in 10 mL | Injection | |
| Concentrated injection containing pamidronate disodium 60 mg in 10 mL | Injection | |
| Pancreatic extract | Capsule (containing enteric coated minimicrospheres) providing not less than 10,000 BP units of lipase activity | Oral |
| Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity | Oral | |
| Capsule (containing enteric coated minimicrospheres) providing not less than 35,000 BP units of lipase activity | Oral | |
| Granules (enteric coated) providing not less than 5,000 BP units of lipase activity per 100 mg, 20 g | Oral | |
| Pancrelipase | Capsule (containing enteric coated microtablets) providing not less than 25,000 BP units of lipase activity | Oral |
| Capsule (containing enteric coated microtablets) providing not less than 25,000 BP units of lipase activity (s19A) | Oral | |
| Pantoprazole | Sachet containing granules 40 mg (as sodium sesquihydrate) | Oral |
| Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | |
| Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | |
| Paracetamol | Oral liquid 120 mg per 5 mL, 100 mL | Oral |
| Oral liquid 240 mg per 5 mL, 200 mL | Oral | |
| Suppository 500 mg | Rectal | |
| Tablet 500 mg | Oral | |
| Tablet 665 mg (modified release) | Oral | |
| Paraffin | Eye drops containing liquid paraffin, glycerol, tyloxapol, poloxamer‑188, trometamol hydrochloride, trometamol, cetalkonium chloride, 10 mL (preservative free) | Application to the eye |
| Eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g | Application to the eye | |
| Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g | Application to the eye | |
| Paraffin with retinol palmitate | Eye ointment, compound, containing liquid paraffin, light liquid paraffin, wool fat, white soft paraffin and retinol palmitate, 5 g | Application to the eye |
| Paroxetine | Tablet 20 mg (as hydrochloride) | Oral |
| Pazopanib | Tablet 200 mg (as hydrochloride) | Oral |
| Tablet 400 mg (as hydrochloride) | Oral | |
| Peginterferon alfa‑2a | Injection 135 micrograms in 0.5 mL single use pre‑filled syringe | Injection |
| Injection 180 micrograms in 0.5 mL single use pre‑filled syringe | Injection | |
| Peginterferon beta‑1a | Pack containing single use injection pens containing 63 micrograms in 0.5 mL and 94 micrograms in 0.5 mL | Injection |
| Single use injection pen containing 125 micrograms in 0.5 mL | Injection | |
| Penicillamine | Tablet 125 mg | Oral |
| Tablet 250 mg | Oral | |
| Perampanel | Tablet 10 mg (as hemisesquihydrate) | Oral |
| Tablet 12 mg (as hemisesquihydrate) | Oral | |
| Tablet 2 mg (as hemisesquihydrate) | Oral | |
| Tablet 4 mg (as hemisesquihydrate) | Oral | |
| Tablet 6 mg (as hemisesquihydrate) | Oral | |
| Tablet 8 mg (as hemisesquihydrate) | Oral | |
| Perfluorohexyloctane | Eye drops, 3 mL | Application to the eye |
| Perhexiline | Tablet containing perhexiline maleate 100 mg | Oral |
| Periciazine | Tablet 10 mg | Oral |
| Tablet 2.5 mg | Oral | |
| Perindopril | Tablet containing perindopril arginine 10 mg | Oral |
| Tablet containing perindopril arginine 2.5 mg | Oral | |
| Tablet containing perindopril arginine 5 mg | Oral | |
| Tablet containing perindopril erbumine 2 mg | Oral | |
| Tablet containing perindopril erbumine 4 mg | Oral | |
| Tablet containing perindopril erbumine 8 mg | Oral | |
| Perindopril with amlodipine | Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besilate) | Oral |
| Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besilate) | Oral | |
| Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate) | Oral | |
| Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besilate) | Oral | |
| Perindopril with indapamide | Tablet containing perindopril arginine 2.5 mg with indapamide hemihydrate 0.625 mg | Oral |
| Tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg | Oral | |
| Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | |
| Permethrin | Cream 50 mg per g, 30 g | Application |
| Phenelzine | Tablet 15 mg (as sulfate) | Oral |
| Tablet 15 mg (as sulfate) (USP) | Oral | |
| Phenobarbital | Injection 200 mg (as sodium) in 1 mL |
| Tablet 30 mg | Oral | |
| Phenoxybenzamine | Capsule containing phenoxybenzamine hydrochloride 10 mg | Oral |
| Capsules containing phenoxybenzamine hydrochloride 10 mg, 30 | Oral | |
| Phenoxymethylpenicillin | Capsule 250 mg phenoxymethylpenicillin (as potassium) | Oral |
| Capsule 500 mg phenoxymethylpenicillin (as potassium) | Oral | |
| Oral suspension 150 mg (as benzathine) per 5 mL, 100 mL | Oral | |
| Powder for oral liquid 125 mg (as potassium) per 5 mL, 100 mL | Oral | |
| Powder for oral liquid 250 mg (as potassium) per 5 mL, 100 mL | Oral | |
| Tablet 250 mg phenoxymethylpenicillin (as potassium) | Oral | |
| Tablet 500 mg phenoxymethylpenicillin (as potassium) | Oral | |
| Phenylalanine with carbohydrate | Sachets of oral powder 4 g containing 50 mg phenylalanine, 30 (Phenylalanine 50) | Oral |
| Phenytoin | Capsule containing phenytoin sodium 100 mg | Oral |
| Capsule containing phenytoin sodium 30 mg | Oral | |
| Oral suspension 30 mg per 5 mL, 500 mL | Oral | |
| Tablet 50 mg | Oral | |
| Pilocarpine | Eye drops containing pilocarpine hydrochloride 10 mg per mL, 15 mL | Application to the eye |
| Eye drops containing pilocarpine hydrochloride 20 mg per mL, 15 mL | Application to the eye | |
| Eye drops containing pilocarpine hydrochloride 40 mg per mL, 15 mL | Application to the eye | |
| Pimecrolimus | Cream 10 mg per g, 15 g | Application |
| Pindolol | Tablet 5 mg | Oral |
| Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral |
| Tablet 30 mg (as hydrochloride) | Oral | |
| Tablet 45 mg (as hydrochloride) | Oral | |
| Pirfenidone | Capsule 267 mg | Oral |
| Tablet 267 mg | Oral | |
| Tablet 801mg | Oral | |
| Piroxicam | Capsule 10 mg | Oral |
| Capsule 20 mg | Oral | |
| Dispersible tablet 10 mg | Oral | |
| Dispersible tablet 20 mg | Oral | |
| Pizotifen | Tablet 500 micrograms (as malate) | Oral |
| Polyethylene glycol 400 with propylene glycol | Eye drops 4 mg‑3 mg per mL, 15 mL | Application to the eye |
| Eye drops 4 mg‑3 mg per mL, single dose units 0.8 mL, 28 | Application to the eye | |
| Poly‑l‑lactic acid | Powder for injection 150 mg | Injection |
| Polyvinyl alcohol | Eye drops 14 mg per mL, 15 mL | Application to the eye |
| Ponatinib | Tablet 15 mg (as hydrochloride) | Oral |
| Tablet 45 mg (as hydrochloride) | Oral | |
| Posaconazole | Tablet (modified release) 100 mg | Oral |
| Potassium chloride | Tablet 600 mg (sustained release) | Oral |
| Potassium chloride with potassium bicarbonate | Tablet, effervescent, 14 mmol potassium and 8 mmol chloride | Oral |
| Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 1.5 mg | Oral |
| Tablet (extended release) containing pramipexole dihydrochloride monohydrate 2.25 mg | Oral | |
| Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3 mg | Oral | |
| Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3.75 mg | Oral | |
| Tablet (extended release) containing pramipexole dihydrochloride monohydrate 375 micrograms | Oral | |
| Tablet (extended release) containing pramipexole dihydrochloride monohydrate 4.5 mg | Oral | |
| Tablet (extended release) containing pramipexole dihydrochloride monohydrate 750 micrograms | Oral | |
| Tablet containing pramipexole dihydrochloride monohydrate 1 mg | Oral | |
| Tablet containing pramipexole dihydrochloride monohydrate 125 micrograms | Oral | |
| Tablet containing pramipexole dihydrochloride monohydrate 250 micrograms | Oral | |
| Pravastatin | Tablet containing pravastatin sodium 10 mg | Oral |
| Tablet containing pravastatin sodium 20 mg | Oral | |
| Tablet containing pravastatin sodium 40 mg | Oral | |
| Tablet containing pravastatin sodium 80 mg | Oral | |
| Praziquantel | Tablet 600 mg | Oral |
| Prazosin | Tablet 1 mg (as hydrochloride) | Oral |
| Tablet 2 mg (as hydrochloride) | Oral | |
| Tablet 5 mg (as hydrochloride) | Oral | |
| Prednisolone | Enema, retention, 20 mg (as sodium phosphate) in 100 mL | Rectal |
| Oral solution 5 mg (as sodium phosphate) per mL, 30 mL | Oral | |
| Suppositories 5 mg (as sodium phosphate), 10 | Rectal | |
| Tablet 1 mg | Oral | |
| Tablet 25 mg | Oral | |
| Tablet 5 mg | Oral | |
| Prednisolone acetate | Eye drops containing prednisolone acetate 10 mg per mL, 10 mL | Application to the eye |
| Prednisolone with phenylephrine | Eye drops containing prednisolone acetate 10 mg with phenylephrine hydrochloride 1.2 mg per mL, 10 mL | Application to the eye |
| Prednisone | Tablet 1 mg | Oral |
| Tablet 25 mg | Oral | |
| Tablet 5 mg | Oral | |
| Pregabalin | Capsule 150 mg | Oral |
| Capsule 25 mg | Oral | |
| Capsule 300 mg | Oral | |
| Capsule 75 mg | Oral | |
| Primidone | Tablet 250 mg | Oral |
| Tablet 250 mg (USP) | Oral | |
| Probenecid | Tablet 500 mg | Oral |
| Procaine benzylpenicillin | Injection 1.5 g in disposable syringe | Injection |
| Prochlorperazine | Injection containing prochlorperazine mesilate 12.5 mg in 1 mL | Injection |
| Tablet containing prochlorperazine maleate 5 mg | Oral | |
| Progesterone | Capsule 200 mg | Vaginal |
| Pessary 200 mg | Vaginal | |
| Promethazine | Injection containing promethazine hydrochloride 50 mg in 2 mL | Injection |
| Propantheline | Tablet containing propantheline bromide 15 mg | Oral |
| Propranolol | Tablet containing propranolol hydrochloride 10 mg | Oral |
| Tablet containing propranolol hydrochloride 160 mg | Oral | |
| Tablet containing propranolol hydrochloride 40 mg | Oral | |
| Propylthiouracil | Tablet 50 mg | Oral |
| Protein formula with amino acids, carbohydrates, vitamins and minerals without phenylalanine, and supplemented with docosahexaenoic acid | Oral liquid 130 mL, 30 (PKU Easy) | Oral |
| Protein formula with carbohydrate, fat, vitamins and minerals | Oral liquid 500 mL, 12 (Nutrini Peptisorb Energy) | Oral |
| Protein formula with vitamins and minerals, and low in potassium, phosphorus, calcium, chloride and vitamin A | Oral liquid 125 mL, 24 (Renastep) | Oral |
| Protein hydrolysate formula with medium chain triglycerides | Oral powder 400 g (Alfaré) | Oral |
| Oral powder 450 g (Aptamil Gold+ Pepti‑Junior) | Oral | |
| Pyrantel | Tablet 125 mg (as embonate) | Oral |
| Tablet 250 mg (as embonate) | Oral | |
| Pyridostigmine | Tablet containing pyridostigmine bromide 10 mg | Oral |
| Tablet containing pyridostigmine bromide 180 mg (modified release) | Oral | |
| Tablet containing pyridostigmine bromide 60 mg | Oral | |
| Quetiapine | Tablet (modified release) 150 mg (as fumarate) | Oral |
| Tablet (modified release) 200 mg (as fumarate) | Oral | |
| Tablet (modified release) 300 mg (as fumarate) | Oral | |
| Tablet (modified release) 400 mg (as fumarate) | Oral | |
| Tablet (modified release) 50 mg (as fumarate) | Oral | |
| Tablet 100 mg (as fumarate) | Oral | |
| Tablet 200 mg (as fumarate) | Oral | |
| Tablet 25 mg (as fumarate) | Oral | |
| Tablet 300 mg (as fumarate) | Oral | |
| Quinagolide | Tablet 75 micrograms (as hydrochloride) | Oral |
| Quinapril | Tablet 10 mg (as hydrochloride) | Oral |
| Tablet 20 mg (as hydrochloride) | Oral | |
| Tablet 5 mg (as hydrochloride) | Oral | |
| Quinapril with hydrochlorothiazide | Tablet 10 mg quinapril (as hydrochloride) with 12.5 mg hydrochlorothiazide | Oral |
| Tablet 20 mg quinapril (as hydrochloride) with 12.5 mg hydrochlorothiazide | Oral | |
| Quinine | Tablet containing quinine sulfate dihydrate 300 mg | Oral |
| Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral |
| Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | |
| Raloxifene | Tablet containing raloxifene hydrochloride 60 mg | Oral |
| Ramipril | Capsule 1.25 mg | Oral |
| Capsule 10 mg | Oral | |
| Capsule 2.5 mg | Oral | |
| Capsule 5 mg | Oral | |
| Tablet 1.25 mg | Oral | |
| Tablet 10 mg | Oral | |
| Tablet 2.5 mg | Oral | |
| Tablet 5 mg | Oral | |
| Ramipril with felodipine | Tablet 2.5 mg‑2.5 mg (modified release) | Oral |
| Tablet 5 mg‑5 mg (modified release) | Oral | |
| Ranibizumab | Solution for intravitreal injection 1.65 mg in 0.165 mL pre‑filled syringe | Injection |
| Solution for intravitreal injection 2.3 mg in 0.23 mL | Injection | |
| Ranitidine | Syrup 150 mg (as hydrochloride) per 10 mL, 300 mL | Oral |
| Tablet 150 mg (as hydrochloride) | Oral | |
| Tablet 300 mg (as hydrochloride) | Oral | |
| Rasagiline | Tablet 1 mg (as mesilate) | Oral |
| Reboxetine | Tablet 4 mg (as mesilate) | Oral |
| Reteplase | Pack containing 2 vials powder for injection 10 units, 2 single use pre‑filled syringes with solvent, 2 reconstitution spikes and 2 needles | Injection |
| Ribavirin | Tablet 200 mg | Oral |
| Ribociclib | Tablet 200 mg | Oral |
| Rifampicin | Capsule 150 mg | Oral |
| Capsule 300 mg | Oral | |
| Syrup 100 mg per 5 mL, 60 mL | Oral | |
| Rifaximin | Tablet 550 mg | Oral |
| Riluzole | Oral suspension 50 mg per 10 mL, 300 mL | Oral |
| Tablet 50 mg | Oral | |
| Ripretinib | Tablet 50 mg | Oral |
| Risankizumab | Injection 75 mg in 0.83 mL pre‑filled syringe | Injection |
| Risedronic acid | Tablet (enteric coated) containing risedronate sodium 35 mg | Oral |
| Tablet containing risedronate sodium 150 mg | Oral | |
| Tablet containing risedronate sodium 30 mg | Oral | |
| Tablet containing risedronate sodium 35 mg | Oral | |
| Tablet containing risedronate sodium 5 mg | Oral | |
| Risedronic acid and calcium | Pack containing 4 tablets risedronate sodium 35 mg and 24 tablets calcium 500 mg (as carbonate) | Oral |
| Risperidone | I.M. injection (modified release), set containing 1 vial powder for injection 25 mg and 1 pre‑filled syringe diluent 2 mL | Injection |
| I.M. injection (modified release), set containing 1 vial powder for injection 37.5 mg and 1 pre‑filled syringe diluent 2 mL | Injection | |
| I.M. injection (modified release), set containing 1 vial powder for injection 50 mg and 1 pre‑filled syringe diluent 2 mL | Injection | |
| Oral solution 1 mg per mL, 100 mL | Oral | |
| Tablet 0.5 mg | Oral | |
| Tablet 1 mg | Oral | |
| Tablet 2 mg | Oral | |
| Tablet 3 mg | Oral | |
| Tablet 4 mg | Oral | |
| Rivaroxaban | Tablet 2.5 mg | Oral |
| Tablet 10 mg | Oral | |
| Tablet 15 mg | Oral | |
| Tablet 20 mg | Oral | |
| Rivastigmine | Capsule 1.5 mg (as hydrogen tartrate) | Oral |
| Capsule 3 mg (as hydrogen tartrate) | Oral | |
| Capsule 4.5 mg (as hydrogen tartrate) | Oral | |
| Capsule 6 mg (as hydrogen tartrate) | Oral | |
| Transdermal patch 18 mg | Transdermal | |
| Transdermal patch 27 mg | Transdermal | |
| Transdermal patch 9 mg | Transdermal | |
| Rizatriptan | Tablet (orally disintegrating) 10 mg (as benzoate) | Oral |
| Wafer 10 mg (as benzoate) | Oral | |
| Romosozumab | Injection 105 mg in 1.17 mL single use pre‑filled syringe | Injection |
| Rosuvastatin | Tablet 10 mg (as calcium) | Oral |
| Tablet 20 mg (as calcium) | Oral | |
| Tablet 40 mg (as calcium) | Oral | |
| Tablet 5 mg (as calcium) | Oral | |
| Rotigotine | Transdermal patch 13.5 mg | Transdermal |
| Transdermal patch 18 mg | Transdermal | |
| Transdermal patch 4.5 mg | Transdermal | |
| Transdermal patch 9 mg | Transdermal | |
| Roxithromycin | Tablet 150 mg | Oral |
| Tablet 300 mg | Oral | |
| Tablet for oral suspension 50 mg | Oral | |
| Ruxolitinib | Tablet 10 mg | Oral |
| Tablet 15 mg | Oral | |
| Tablet 20 mg | Oral | |
| Tablet 5 mg | Oral | |
| Sacubitril with valsartan | Tablet containing sacubitril 24.3 mg with valsartan 25.7 mg | Oral |
| Tablet containing sacubitril 48.6 mg with valsartan 51.4 mg | Oral | |
| Tablet containing sacubitril 97.2 mg with valsartan 102.8 mg | Oral | |
| Safinamide | Tablet 100 mg | Oral |
| Tablet 50 mg | Oral | |
| Salbutamol | Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20 | Inhalation |
| Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30 | Inhalation | |
| Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 20 | Inhalation | |
| Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30 | Inhalation | |
| Oral solution 2 mg (as sulfate) per 5 mL, 150 mL | Oral | |
| Pressurised inhalation in breath actuated device 100 micrograms (as sulfate) per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth | |
| Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth | |
| Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC‑free formulation) | Inhalation by mouth | |
| Salmeterol | Powder for oral inhalation in breath actuated device 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth |
| Sapropterin | Powder for oral solution 500 mg (as dihydrochloride) | Oral |
| Tablet (soluble) containing sapropterin dihydrochloride 100 mg | Oral | |
| Saxagliptin | Tablet 2.5 mg (as hydrochloride) | Oral |
| Tablet 5 mg (as hydrochloride) | Oral | |
| Saxagliptin with dapagliflozin | Tablet containing saxagliptin 5 mg with dapaglifozin 10 mg | Oral |
| Saxagliptin with metformin | Tablet (modified release) containing 2.5 mg saxagliptin (as hydrochloride) with 1000 mg metformin hydrochloride | Oral |
| Tablet (modified release) containing 5 mg saxagliptin (as hydrochloride) with 1000 mg metformin hydrochloride | Oral | |
| Tablet (modified release) containing 5 mg saxagliptin (as hydrochloride) with 500 mg metformin hydrochloride | Oral | |
| Secukinumab | Injection 150 mg in 1 mL pre‑filled pen | Injection |
| Selegiline | Tablet containing selegiline hydrochloride 5 mg | Oral |
| Semaglutide | Solution for injection 2 mg in 1.5 mL pre‑filled pen | Injection |
| Solution for injection 4 mg in 3 mL pre‑filled pen | Injection | |
| Sertraline | Tablet 50 mg (as hydrochloride) | Oral |
| Tablet 100 mg (as hydrochloride) | Oral | |
| Sevelamer | Tablet containing sevelamer carbonate 800 mg | Oral |
| Tablet containing sevelamer hydrochloride 800 mg | Oral | |
| Silver sulfadiazine | Cream 10 mg per g, 50 g | Application |
| Simvastatin | Tablet 10 mg | Oral |
| Tablet 20 mg | Oral | |
| Tablet 40 mg | Oral | |
| Tablet 5 mg | Oral | |
| Tablet 80 mg | Oral | |
| Siponimod | Tablet 250 micrograms (as hemifumarate) | Oral |
| Tablet 2 mg (as hemifumarate) | Oral | |
| Sirolimus | Oral solution 1 mg per mL, 60 mL | Oral |
| Tablet 0.5 mg | Oral | |
| Tablet 1 mg | Oral | |
| Tablet 2 mg | Oral | |
| Sitagliptin | Tablet 100 mg (as phosphate monohydrate) | Oral |
| Tablet 25 mg (as phosphate monohydrate) | Oral | |
| Tablet 50 mg (as phosphate monohydrate) | Oral | |
| Sitagliptin with metformin | Tablet (modified release) containing 100 mg sitagliptin (as phosphate monohydrate) with 1000 mg metformin hydrochloride | Oral |
| Tablet (modified release) containing 50 mg sitagliptin (as phosphate monohydrate) with 1000 mg metformin hydrochloride | Oral | |
| Tablet containing 50 mg sitagliptin (as phosphate monohydrate) with 1000 mg metformin hydrochloride | Oral | |
| Tablet containing 50 mg sitagliptin (as phosphate monohydrate) with 500 mg metformin hydrochloride | Oral | |
| Tablet containing 50 mg sitagliptin (as phosphate monohydrate) with 850 mg metformin hydrochloride | Oral | |
| Sodium acid phosphate | Tablet, compound effervescent, equivalent to 500 mg phosphorus | Oral |
| Sodium bicarbonate | Capsule 840 mg | Oral |
| Sodium phenylbutyrate | Granules 483 mg per g, 174 g | Oral |
| Sofosbuvir with velpatasvir | Tablet containing 400 mg sofosbuvir with 100 mg velpatasvir | Oral |
| Sofosbuvir with velpatasvir and voxilaprevir | Tablet containing 400 mg sofosbuvir with 100 mg velpatasvir and 100 mg voxilaprevir | Oral |
| Sonidegib | Capsule 200 mg | Oral |
| Sorafenib | Tablet 200 mg (as tosilate) | Oral |
| Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate | Enemas 3.125 g‑450 mg‑45 mg in 5 mL, 12 | Rectal |
| Sotalol | Tablet containing sotalol hydrochloride 160 mg | Oral |
| Tablet containing sotalol hydrochloride 80 mg | Oral | |
| Soy lecithin | Eye spray 10 mg per mL, 10 mL | Application |
| Soy protein and fat formula with vitamins and minerals ‑‑ carbohydrate free | Oral liquid 384 mL (RCF) | Oral |
| Spironolactone | Tablet 100 mg | Oral |
| Tablet 25 mg | Oral | |
| Sterculia with frangula bark | Granules 620 mg‑80 mg per g, 500 g | Oral |
| Stiripentol | Capsule 250 mg | Oral |
| Capsule 500 mg | Oral | |
| Powder for oral suspension 250 mg | Oral | |
| Powder for oral suspension 500 mg | Oral | |
| Sucroferric oxyhydroxide | Tablet, chewable, 2.5 g (equivalent to 500 mg iron) | Oral |
| Sulfasalazine | Tablet 500 mg | Oral |
| Tablet 500 mg (enteric coated) | Oral | |
| Sulthiame | Tablet 200 mg | Oral |
| Tablet 50 mg | Oral | |
| Sumatriptan | Nasal spray 20 mg in 0.1 mL single dose unit | Nasal |
| Tablet (fast disintegrating) 50 mg (as succinate) | Oral | |
| Tablet 50 mg (as succinate) | Oral | |
| Sunitinib | Capsule 12.5 mg | Oral |
| Capsule 25 mg | Oral | |
| Capsule 37.5 mg | Oral | |
| Capsule 50 mg | Oral | |
| Tacrolimus | Capsule 0.5 mg | Oral |
| Capsule 0.5 mg (once daily prolonged release) | Oral | |
| Capsule 0.75 mg | Oral | |
| Capsule 1 mg | Oral | |
| Capsule 1 mg (once daily prolonged release) | Oral | |
| Capsule 2 mg | Oral | |
| Capsule 3 mg (once daily prolonged release) | Oral | |
| Capsule 5 mg | Oral | |
| Capsule 5 mg (once daily prolonged release) | Oral | |
| Tafluprost | Eye drops 15 micrograms per mL, single dose units 0.3 mL, 30 | Application to the eye |
| Tamoxifen | Tablet 20 mg (as citrate) | Oral |
| Tapentadol | Tablet (modified release) 100 mg (as hydrochloride) | Oral |
| Tablet (modified release) 150 mg (as hydrochloride) | Oral | |
| Tablet (modified release) 200 mg (as hydrochloride) | Oral | |
| Tablet (modified release) 250 mg (as hydrochloride) | Oral | |
| Tablet (modified release) 50 mg (as hydrochloride) | Oral | |
| Telmisartan | Tablet 40 mg | Oral |
| Tablet 80 mg | Oral | |
| Telmisartan with amlodipine | Tablet 40 mg‑10 mg (as besilate) | Oral |
| Tablet 40 mg‑5 mg (as besilate) | Oral | |
| Tablet 80 mg‑10 mg (as besilate) | Oral | |
| Tablet 80 mg‑5 mg (as besilate) | Oral | |
| Telmisartan with hydrochlorothiazide | Tablet 40 mg‑12.5 mg | Oral |
| Tablet 80 mg‑12.5 mg | Oral | |
| Tablet 80 mg‑25 mg | Oral | |
| Temazepam | Tablet 10 mg | Oral |
| Temozolomide | Capsule 100 mg | Oral |
| Capsule 140 mg | Oral | |
| Capsule 180 mg | Oral | |
| Capsule 20 mg | Oral | |
| Capsule 250 mg | Oral | |
| Capsule 5 mg | Oral | |
| Tenecteplase | Powder for injection 40 mg with solvent | Injection |
| Powder for injection 50 mg with solvent | Injection | |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral |
| Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg | Oral | |
| Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg | Oral | |
| Tablet containing tenofovir disoproxil succinate 301 mg with emtricitabine 200 mg | Oral | |
| Terbinafine | Cream containing terbinafine hydrochloride 10 mg per g, 15 g | Application |
| Tablet 250 mg (as hydrochloride) | Oral | |
| Terbutaline | Injection containing terbutaline sulfate 500 micrograms in 1 mL | Injection |
| Powder for oral inhalation in breath actuated device containing terbutaline sulfate 500 micrograms per dose, 120 doses | Inhalation by mouth | |
| Teriflunomide | Tablet 14 mg | Oral |
| Teriparatide | Injection 250 micrograms per mL, 2.4 mL in multi‑dose pre‑filled cartridge | Injection |
| Testosterone | I.M. injection containing testosterone undecanoate 1,000 mg in 4 mL | Injection |
| Transdermal cream 50 mg per mL, 50 mL | Transdermal | |
| Transdermal gel (pump pack) 12.5 mg per 1.25 g dose, 60 doses, 2 | Transdermal | |
| Transdermal gel (pump pack) 23 mg per 1.15 g dose, 56 doses | Transdermal | |
| Transdermal gel 50 mg in 5 g sachet, 30 | Transdermal | |
| Transdermal patches 24.3 mg, 30 | Transdermal | |
| Tetrabenazine | Tablet 25 mg | Oral |
| Tetracosactide | Compound depot injection 1 mg in 1 mL | Injection |
| Theophylline | Oral solution 133.3 mg per 25 mL, 500 mL | Oral |
| Tablet 200 mg (sustained release) | Oral | |
| Tablet 250 mg (sustained release) | Oral | |
| Tablet 300 mg (sustained release) | Oral | |
| Thiamine | Tablet containing thiamine hydrochloride 100 mg | Oral |
| Thyrotropin alfa | Powder for injection 0.9 mg, 2 | Injection |
| Tiagabine | Tablet 10 mg (as hydrochloride) | Oral |
| Tablet 15 mg (as hydrochloride) | Oral | |
| Tablet 5 mg (as hydrochloride) | Oral | |
| Ticagrelor | Tablet 90 mg | Oral |
| Tildrakizumab | Injection 100 mg in 1 mL single dose pre‑filled syringe | Injection |
| Timolol | Eye drops (gellan gum solution) 5 mg (as maleate) per mL, 2.5 mL | Application to the eye |
| Eye drops 5 mg (as maleate) per mL, 5 mL | Application to the eye | |
| Tioguanine | Tablet 40 mg | Oral |
| Tiotropium | Capsule containing powder for oral inhalation 13 micrograms (as bromide) (for use in Zonda device) | Inhalation by Mouth |
| Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate) (for use in HandiHaler) | Inhalation by mouth | |
| Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations) | Inhalation by mouth | |
| Tiotropium with olodaterol | Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses | Inhalation by mouth |
| Tirofiban | Solution concentrate for I.V. infusion 12.5 mg (as hydrochloride) in 50 mL | Injection |
| Tobramycin | Capsule containing powder for oral inhalation 28 mg (for use in podhaler) | Inhalation by mouth |
| Eye drops 3 mg per mL, 5 mL | Application to the eye | |
| Eye ointment 3 mg per g, 3.5 g | Application to the eye | |
| Injection 500 mg (as sulfate) in 5 mL (without preservative) | Injection | |
| Injection 80 mg (as sulfate) in 2 mL (without preservative) | Injection | |
| Injection 80 mg in 2 mL | Injection | |
| Solution for inhalation 300 mg in 5 mL | Inhalation | |
| Tocilizumab | Injection 162 mg in 0.9 mL single use pre‑filled pen | Injection |
| Injection 162 mg in 0.9 mL single use pre‑filled syringe | Injection | |
| Tofacitinib | Tablet 5 mg | Oral |
| Tablet 10 mg | Oral | |
| Tolvaptan | Pack containing 28 tablets 15 mg and 28 tablets 45 mg | Oral |
| Pack containing 28 tablets 30 mg and 28 tablets 60 mg | Oral | |
| Pack containing 28 tablets 30 mg and 28 tablets 90 mg | Oral | |
| Tablet 15 mg | Oral | |
| Tablet 30 mg | Oral | |
| Topiramate | Capsule 15 mg | Oral |
| Capsule 25 mg | Oral | |
| Capsule 50 mg | Oral | |
| Tablet 100 mg | Oral | |
| Tablet 200 mg | Oral | |
| Tablet 25 mg | Oral | |
| Tablet 50 mg | Oral | |
| Toremifene | Tablet 60 mg (as citrate) | Oral |
| Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral |
| Injection containing tramadol hydrochloride 100 mg in 2 mL | Injection | |
| Oral drops containing tramadol hydrochloride 100 mg per mL, 10 mL | Oral | |
| Tablet (sustained release) containing tramadol hydrochloride 100 mg | Oral | |
| Tablet (sustained release) containing tramadol hydrochloride 150 mg | Oral | |
| Tablet (sustained release) containing tramadol hydrochloride 200 mg | Oral | |
| Tablet (sustained release) containing tramadol hydrochloride 50 mg | Oral | |
| Trametinib | Tablet 2 mg | Oral |
| Tablet 500 micrograms | Oral | |
| Trandolapril | Capsule 1 mg | Oral |
| Capsule 2 mg | Oral | |
| Capsule 4 mg | Oral | |
| Capsule 500 micrograms | Oral | |
| Trandolapril with verapamil | Tablet containing trandolapril 2 mg with verapamil hydrochloride 180 mg (sustained release) | Oral |
| Tablet containing trandolapril 4 mg with verapamil hydrochloride 240 mg (sustained release) | Oral | |
| Tranexamic acid | Tablet 500 mg | Oral |
| Tranylcypromine | Tablet 10 mg (as sulfate) | Oral |
| Trastuzumab | Solution for subcutaneous injection containing trastuzumab 600 mg in 5 mL | Injection |
| Travoprost | Eye drops 40 micrograms per mL, 2.5 mL | Application to the eye |
| Travoprost with timolol | Eye drops 40 micrograms travoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the eye |
| Triamcinolone | Cream containing triamcinolone acetonide 200 micrograms per g, 100 g | Application |
| Injection containing triamcinolone acetonide 10 mg in 1 mL | Injection | |
| Ointment containing triamcinolone acetonide 200 micrograms per g, 100 g | Application | |
| Triamcinolone with neomycin, gramicidin and nystatin | Ear drops containing triamcinolone acetonide 0.9 mg with neomycin 2.25 mg (as sulfate), gramicidin 225 micrograms and nystatin 90,000 units per mL, 7.5 mL | Application to the ear |
| Ear ointment containing triamcinolone acetonide 1 mg with neomycin 2.5 mg (as sulfate), gramicidin 250 micrograms and nystatin 100,000 units per g, 5 g | Application to the ear | |
| Trifluridine with tipiracil | Tablet containing 15 mg trifluridine with 6.14 mg tipiracil (as hydrochloride) | Oral |
| Tablet containing 20 mg trifluridine with 8.19 mg tipiracil (as hydrochloride) | Oral | |
| Triglycerides ‑ medium chain, formula | Oral liquid 500 mL, 8 (Nutrini Peptisorb) | Oral |
| Oral powder 400 g (Lipistart) | Oral | |
| Oral powder 400 g (Monogen) | Oral | |
| Oral powder 400 g (Peptamen Junior) | Oral | |
| Sachets containing oral powder 16 g, 30 (MCT Pro‑Cal) | Oral | |
| Triglycerides, long chain with glucose polymer | Oral liquid 1 L, 6 (ProZero) | Oral |
| Oral liquid 200 mL, 27 (Sno‑Pro) | Oral | |
| Oral liquid 250 mL, 18 (ProZero) | Oral | |
| Triglycerides, medium chain | Oil 500 mL (MCT Oil) | Oral |
| Oral emulsion 250 mL (Liquigen) | Oral | |
| Oral liquid 225 mL, 15 (betaquik) | Oral | |
| Triglycerides, medium chain and long chain with glucose polymer | Oral powder 400 g (Duocal) | Oral |
| Trihexyphenidyl | Tablet containing trihexyphenidyl hydrochloride 2 mg | Oral |
| Tablet containing trihexyphenidyl hydrochloride 5 mg | Oral | |
| Trimethoprim | Tablet 300 mg | Oral |
| Trimethoprim with sulfamethoxazole | Paediatric oral suspension 40 mg‑200 mg per 5 mL, 100 mL | Oral |
| Tablet 160 mg‑800 mg | Oral | |
| Triptorelin | Powder for I.M. injection (prolonged release) 11.25 mg (as embonate) with solvent, syringe and needles | Injection |
| Powder for I.M. injection (prolonged release) 22.5 mg (as embonate) with solvent, syringe and needles | Injection | |
| Powder for I.M. injection (prolonged release) 3.75 mg (as embonate) with solvent, syringe and needles | Injection | |
| Tropisetron | I.V. injection 5 mg (as hydrochloride) in 5 mL | Injection |
| Tyrosine with carbohydrate | Sachets of oral powder 4 g containing 1 g tyrosine, 30 (Tyrosine 1000) | Oral |
| Umeclidinium | Powder for oral inhalation in breath actuated device 62.5 micrograms (as bromide) per dose, 30 doses | Inhalation by mouth |
| Umeclidinium with vilanterol | Powder for oral inhalation in breath actuated device containing umeclidinium 62.5 micrograms (as bromide) with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | Inhalation by mouth |
| Upadacitinib | Tablet 15 mg | Oral |
| Tablet 30 mg | Oral | |
| Ursodeoxycholic acid | Capsule 250 mg | Oral |
| Tablet 500 mg | Oral | |
| Ustekinumab | Injection 45 mg in 0.5 mL | Injection |
| Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral |
| Valine with carbohydrate | Sachets of oral powder 4 g containing 1 g valine, 30 (Valine 1000) | Oral |
| Sachets of oral powder 4 g containing 50 mg valine, 30 (Valine 50) | Oral | |
| Valproic acid | Oral liquid containing sodium valproate 200 mg per 5 mL, 300 mL | Oral |
| Oral solution containing sodium valproate 200 mg per 5 mL, 300 mL | Oral | |
| Tablet (enteric coated) containing sodium valproate 200 mg | Oral | |
| Tablet (enteric coated) containing sodium valproate 500 mg | Oral | |
| Tablet, crushable, containing sodium valproate 100 mg | Oral | |
| Valsartan | Tablet 160 mg | Oral |
| Tablet 320 mg | Oral | |
| Tablet 40 mg | Oral | |
| Tablet 80 mg | Oral | |
| Valsartan with hydrochlorothiazide | Tablet 160 mg‑12.5 mg | Oral |
| Tablet 160 mg‑25 mg | Oral | |
| Tablet 320 mg‑12.5 mg | Oral | |
| Tablet 320 mg‑25 mg | Oral | |
| Tablet 80 mg‑12.5 mg | Oral | |
| Vancomycin | Capsule 125 mg (125,000 I.U.) (as hydrochloride) | Oral |
| Capsule 250 mg (250,000 I.U.) (as hydrochloride) | Oral | |
| Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride) | Injection | |
| Powder for injection 500 mg (500,000 I.U.) (as hydrochloride) | Injection | |
| Varenicline | Box containing 11 tablets 0.5 mg (as tartrate) and 14 tablets 1 mg (as tartrate) in the first pack and 28 tablets 1 mg (as tartrate) in the second pack | Oral |
| Tablet 1 mg (as tartrate) | Oral | |
| Vedolizumab | Injection 108 mg in 0.68 mL single use pre‑filled pen | Injection |
| Vemurafenib | Tablet 240 mg | Oral |
| Venetoclax | Pack containing 14 tablets venetoclax 10 mg and 7 tablets venetoclax 50 mg and 7 tablets venetoclax 100 mg and 14 tablets venetoclax 100 mg | Oral |
| Tablet 10 mg | Oral | |
| Tablet 100 mg | Oral | |
| Tablet 50 mg | Oral | |
| Venlafaxine | Capsule (modified release) 150 mg (as hydrochloride) | Oral |
| Capsule (modified release) 37.5 mg (as hydrochloride) | Oral | |
| Capsule (modified release) 75 mg (as hydrochloride) | Oral | |
| Verapamil | Tablet containing verapamil hydrochloride 180 mg (sustained release) | Oral |
| Tablet containing verapamil hydrochloride 240 mg (sustained release) | Oral | |
| Tablet containing verapamil hydrochloride 80 mg | Oral | |
| Vigabatrin | Oral powder, sachet 500 mg | Oral |
| Tablet 500 mg | Oral | |
| Vildagliptin | Tablet 50 mg | Oral |
| Vildagliptin with metformin | Tablet containing 50 mg vildagliptin with 1000 mg metformin hydrochloride | Oral |
| Tablet containing 50 mg vildagliptin with 500 mg metformin hydrochloride | Oral | |
| Tablet containing 50 mg vildagliptin with 850 mg metformin hydrochloride | Oral | |
| Vinorelbine | Capsule 20 mg (as tartrate) | Oral |
| Capsule 30 mg (as tartrate) | Oral | |
| Vismodegib | Capsule 150 mg | Oral |
| Vitamins, minerals and trace elements formula | Sachets containing oral powder 7 g, 30 (Phlexy‑Vits) | Oral |
| Vitamins, minerals and trace elements with carbohydrate | Oral powder 200 g (Paediatric Seravit) | Oral |
| Sachets containing oral powder 6 g, 30 (FruitiVits) | Oral | |
| Voriconazole | Powder for oral suspension 40 mg per mL, 70 mL | Oral |
| Tablet 200 mg | Oral | |
| Tablet 50 mg | Oral | |
| Vorinostat | Capsule 100 mg | Oral |
| Warfarin | Tablet containing warfarin sodium 1 mg | Oral |
| Tablet containing warfarin sodium 2 mg | Oral | |
| Tablet containing warfarin sodium 3 mg | Oral | |
| Tablet containing warfarin sodium 5 mg | Oral | |
| Whey protein formula supplemented with amino acids, long chain polyunsaturated fatty acids, vitamins and minerals, and low in protein, phosphate, potassium and lactose | Oral powder 400 g, 6 (Renastart) | Oral |
| Whey protein formula supplemented with amino acids, vitamins and minerals, and low in protein, phosphate, potassium and lactose | Oral powder 400 g (Kindergen) | Oral |
| Zanubrutinib | Capsule 80 mg | Oral |
| Ziprasidone | Capsule 20 mg (as hydrochloride) | Oral |
| Capsule 40 mg (as hydrochloride) | Oral | |
| Capsule 60 mg (as hydrochloride) | Oral | |
| Capsule 80 mg (as hydrochloride) | Oral | |
| Zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection |
| Zolmitriptan | Tablet 2.5 mg | Oral |
| Zonisamide | Capsule 100 mg | Oral |
| Capsule 25 mg | Oral | |
| Capsule 50 mg | Oral | |
| Zuclopenthixol decanoate | Oily I.M. injection 200 mg in 1 mL | Injection |
Endnotes
Endnote 1—About the endnotes
The endnotes provide information about this compilation and the compiled law.
The following endnotes are included in every compilation:
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.
The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.
Editorial changes
The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.
If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.
Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.
If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.
Endnote 2—Abbreviation key
| ad = added or inserted | o = order(s) |
| am = amended | Ord = Ordinance |
| amdt = amendment | orig = original |
| c = clause(s) | par = paragraph(s)/subparagraph(s) |
| C[x] = Compilation No. x | /sub‑subparagraph(s) |
| Ch = Chapter(s) | pres = present |
| def = definition(s) | prev = previous |
| Dict = Dictionary | (prev…) = previously |
| disallowed = disallowed by Parliament | Pt = Part(s) |
| Div = Division(s) | r = regulation(s)/rule(s) |
| ed = editorial change | reloc = relocated |
| exp = expires/expired or ceases/ceased to have | renum = renumbered |
| effect | rep = repealed |
| F = Federal Register of Legislation | rs = repealed and substituted |
| gaz = gazette | s = section(s)/subsection(s) |
| LA = Legislation Act 2003 | Sch = Schedule(s) |
| LIA = Legislative Instruments Act 2003 | Sdiv = Subdivision(s) |
| (md) = misdescribed amendment can be given | SLI = Select Legislative Instrument |
| effect | SR = Statutory Rules |
| (md not incorp) = misdescribed amendment | Sub‑Ch = Sub‑Chapter(s) |
| cannot be given effect | SubPt = Subpart(s) |
| mod = modified/modification | underlining = whole or part not |
| No. = Number(s) | commenced or to be commenced |
Endnote 3—Legislation history
| Name | Registration | Commencement | Application, saving and transitional provisions |
| National Health (Continued Dispensing – Emergency Measures) Determination 2020 | 10 Jan 2020 (F2020L00018) | 13 Jan 2020 (s 1.02) | |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No. 1) (PB 16 of 2020) | 28 Feb 2020 (F2020L00189) | 1 Mar 2020 (s 2) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No.2) (PB 23 of 2020) | 31 Mar 2020 (F2020L00361) | 1 Apr 2020 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No. 3) (PB 36 of 2020) | 30 Apr 2020 (F2020L00522) | 1 May 2020 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No.4) (PB 44 of 2020) | 29 May 2020 (F2020L00643) | 1 June 2020 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No.5) (PB 58 of 2020) | 30 June 2020 (F2020L00848) | 1 July 2020 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No. 6) (PB 70 of 2020) | 31 July 2020 (F2020L00977) | 1 Aug 2020 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No. 7) (PB 81 of 2020) | 27 Aug 2020 (F2020L01070) | 1 Sept 2020 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No. 8) (PB 91 of 2020) | 30 Sept 2020 (F2020L01250) | 1 Oct 2020 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No. 9) (PB 105 of 2020) | 30 Oct 2020 (F2020L01363) | 1 Nov 2020 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No. 10) (PB 114 of 2020) | 27 Nov 2020 (F2020L01495) | 1 Dec 2020 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No. 11) (PB 127 of 2020) | 23 Dec 2020 (F2020L01698) | 1 Jan 2021 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 1) (PB 3 of 2021) | 27 Jan 2021 (F2021L00074) | 1 Feb 2021 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 2) (PB 16 of 2021) | 28 Feb 2021 (F2021L00164) | 1 Mar 2021 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 3) (PB 25 of 2021) | 31 Mar 2021 (F2021L00398) | 1 Apr 2021 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 4) (PB 41 of 2021) | 30 Apr 2021 (F2021L00527) | 1 May 2021 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 5) (PB 49 of 2021) | 28 May 2021 (F2021L00659) | 1 June 2021 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 6) (PB 63 of 2021) | 29 June 2021 (F2021L00898) | 1 July 2021 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 7) (PB 77 of 2021) | 31 July 2021 (F2021L01060) | 1 Aug 2021 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 8) (PB 90 of 2021) | 31 Aug 2021 (F2021L01214) | 1 Sept 2021 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 9) (PB 100 of 2021) | 30 Sept 2021 (F2021L01370) | 1 Oct 2021 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 10) (PB 112 of 2021) | 31 Oct 2021 (F2021L01489) | 1 Nov 2021 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 11) (PB 120 of 2021) | 30 Nov 2021 (F2021L01637) | 1 Dec 2021 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 12) (PB 130 of 2021) | 24 Dec 2021 (F2021L01897) | 1 Jan 2022 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2022 (No. 1) (PB 3 of 2022) | 31 Jan 2022 (F2022L00081) | 1 Feb 2022 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2022 (No. 2) (PB 13 of 2022) | 28 Feb 2022 (F2022L00204) | 1 Mar 2022 (s 2(1) item 1) | — |
| National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2022 (No. 3) (PB 26 of 2022) | 31 Mar 2022 (F2022L00447) | 1 Apr 2022 (s 2(1) item 1) | — |
Endnote 4—Amendment history
| Provision affected | How affected |
| Part 1 | |
| s 1.02........................................ | rep LA s 48D |
| s 1.04........................................ | am F2020L00361 |
| Schedule 1 | |
| Schedule 1................................ | am F2020L00189; F2020L00361; F2020L00522; F2020L00643; F2020L00848; F2020L00977; F2020L01070; F2020L01250; F2020L01363; F2020L01495; F2020L01698; F2021L00074; F2021L00164; F2021L00398; F2021L00527; F2021L00659; F2021L00898; F2021L01060; F2021L01214; F2021L01370; F2021L01489; F2021L01637; F2021L01897 |
| ed C23 | |
| am F2022L00081; F2022L00204; F2022L00447 |
Actions
Download as PDF
Download as Word Document
Cases Citing This Decision
0
Cases Cited
0
Statutory Material Cited
0